It is made available under a CC-BY-NC-ND 4.0 International license.

¹**A germline heterozygous dominant negative** *IKZF2* **variant causing** ²**syndromic primary immune regulatory disorder and ICHAD**

3 Henry Y. Lu^{1,2}, Maryam Vaseghi-Shanjani^{1,2}, Avery J. Lam^{3,4}, Mehul Sharma^{1,2}, Arezoo
4 Mohajeri⁵, Jana Gillies^{3,4}, Gui Xiang Yang⁵, Susan Lin¹, Maggie P. Fu^{5,6,7}, Areesha
5 Salman⁵ Ronak Rah 5 Salman⁵, Ronak Rahmanian⁸, Linlea Armstrong⁵, Jessica Halparin^{1,9}, Connie L. Yang^{1,9},
6 Mark Chilvers^{1,10} Erika Henkelman¹¹ Wingfield Rehmus^{1,12} Douglas Morrison^{1,13} Audi Mark Chilvers^{1,10}, Erika Henkelman¹¹, Wingfield Rehmus^{1,12}, Douglas Morrison^{1,13}, Audi
7 Setiadi^{1,13}, Sara Mostafavi^{5,14}, Michael S. Kobor^{5,7}, Frederick K. Kozak⁸, Catherine M. 7 Setiadi^{1,13}, Sara Mostafavi^{5,14}, Michael S. Kobor^{5,7}, Frederick K. Kozak⁸, Catherine M.
8 Biggs^{1,15} Clara van Karnebeek^{1,7} Kyla J. Hildebrand^{1,15} Anna Lehman on behalf of the 8 Biggs^{1,15}, Clara van Karnebeek^{1,7}, Kyla J. Hildebrand^{1,15}, Anna Lehman on behalf of the
9 Care4Rare Canada Consortium⁵ Megan K. Levings^{3,4,16} Stuart E. Turvey^{1,2,14} 9 Care4Rare Canada Consortium⁵, Megan K. Levings^{3,4,16}, Stuart E. Turvey^{1,2,14}

- 10 ¹Department of Pediatrics, BC Children's Hospital, The University of British Columbia,
11 Mancouver BC Canada
- 11 Vancouver, BC, Canada
12 ²Experimental Medicine
- 12 ²Experimental Medicine Program, Faculty of Medicine, The University of British
13 Columbia Vancouver BC Canada
- 13 Columbia, Vancouver, BC, Canada
14 ³BC Children's Hospital Research Ir
- ³ 3BC Children's Hospital Research Institute, Vancouver, BC, Canada
15 ⁴ Department of Surgery, The University of British Columbia, Vancouv
- 15 ⁴ Department of Surgery, The University of British Columbia, Vancouver, BC, Canada
16 ⁵ Department of Medical Genetics, The University of British Columbia, Vancouver, E
- 16 ⁵Department of Medical Genetics, The University of British Columbia, Vancouver, BC,
17 Canada
- 17 Canada
18 ⁶Genome 18 ⁶ Genome Science and Technology Program, Faculty of Science, The University of
19 British Columbia Vancouver BC Canada
- 19 British Columbia, Vancouver, BC, Canada
20 ⁷ Centre for Molecular Medicine and Therar ⁷ 20⁷ 7 ⁷ Centre for Molecular Medicine and Therapeutics, Vancouver, BC, Canada
21 ⁸ Plivision of Otolaryngology – Head & Neck Surgery, BC, Children's H
- 21 ⁸Division of Otolaryngology Head & Neck Surgery, BC Children's Hospital, The
22 Ethiversity of British Columbia Vancouver BC Canada
- 22 University of British Columbia, Vancouver, BC, Canada
23 ⁹Division of Hematology, Oncology & Bone Marrow Tra 23 ⁹ Division of Hematology, Oncology & Bone Marrow Transplant, BC Children's Hospital, 24 The University of British Columbia Vancouver, BC, Canada
- 24 The University of British Columbia, Vancouver, BC, Canada
25 ¹⁰ Division of Respiratory Medicine, BC Children's Hospita 25 ¹⁰ Division of Respiratory Medicine, BC Children's Hospital, The University of British
26 Columbia Vancouver BC Canada
-
- 26 Columbia, Vancouver, BC, Canada
27 ¹¹ Division of Plastic Surgery, BC Ch 27 ¹¹Division of Plastic Surgery, BC Children's Hospital, The University of British Columbia,
28 Vancouver, BC, Canada
- 28 Vancouver, BC, Canada
29 ¹² Division of Dermatolog 29 ¹²Division of Dermatology, BC Children's Hospital, The University of British Columbia,
30 Nancouver BC Canada
- 30 Vancouver, BC, Canada
31 ¹³Department of Pathol 31 ¹³Department of Pathology and Laboratory Medicine, BC Children's Hospital, The
32 Ethiversity of British Columbia Vancouver BC Canada
- 32 University of British Columbia, Vancouver, BC, Canada
33 ¹⁴Department of Statistics, The University of British Colu
- 14 Department of Statistics, The University of British Columbia, Vancouver, BC, Canada
34 Department of Allergy and Clinical Immunology, BC Children's Hospital. The University of
- 34 ¹⁵Division of Allergy and Clinical Immunology, BC Children's Hospital, The University of
35 British Columbia, Vancouver, BC, Canada
- 35 British Columbia, Vancouver, BC, Canada
36 ¹⁶School of Biomedical Engineering, The University of British Columbia, Vancouver, BC,
37 Canada 37 <mark>Canada</mark>
38
-
- 38
-

medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295301;](https://doi.org/10.1101/2023.09.09.23295301) this version posted September 11, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a CC-BY-NC-ND 4.0 International license.

- **Word count**: 4107
- **Reference count**: 52

It is made available under a CC-BY-NC-ND 4.0 International license.

⁴⁹**Abstract:**

50 Monogenic defects that impair the control of inflammation and tolerance lead to
51 profound immune dysregulation, including autoimmunity and atopy. Studying these 51 profound immune dysregulation, including autoimmunity and atopy. Studying these
52 disorders reveals important molecular and cellular factors that requlate human immune 52 disorders reveals important molecular and cellular factors that regulate human immune
53 bomeostasis and identifies potential precision medicine targets. Here, we provide a 53 homeostasis and identifies potential precision medicine targets. Here, we provide a
54 detailed immunological assessment of a pediatric patient with a recently discovered 54 detailed immunological assessment of a pediatric patient with a recently discovered
55 syndrome causing Immunodysregulation, Craniofacial anomalies, Hearing impairment, ⁵⁵syndrome causing Immunodysregulation, Craniofacial anomalies, Hearing impairment, ⁵⁶Athelia, and Developmental delay (or ICHAD syndrome). The immunodysregulation 57 resulted in autoimmune hemolytic anemia (AIHA) and atopic dermatitis. The patient
58 carried a de novo qermline heterozygous ⁵⁸carried a *de novo* germline heterozygous 59 c.406+540_574+13477dup;p.Gly136_Ser191dup variant in *IKAROS family zinc finger 2 60* (*IKZF2*), which encodes Helios. This variant led to reduced Helios protein expression ⁶⁰(*IKZF2*), which encodes Helios. This variant led to reduced Helios protein expression 61 and dominant interference of wild-type Helios-mediated repression of the *IL2* promoter.
62 Multi-parameter flow cytometric analyses of patient peripheral blood mononuclear cells Multi-parameter flow cytometric analyses of patient peripheral blood mononuclear cells 63 revealed strongly impaired natural killer cell differentiation and function, and increased
64 CD8⁺ T cell activation and cytokine secretion. Strikingly, patient CD4⁺ T cells were 64 $CD8⁺$ T cell activation and cytokine secretion. Strikingly, patient $CD4⁺$ T cells were 65 hyperactive, produced elevated levels of nearly all T helper (T_H) cytokines, and readily 66 proliferated in response to stimulation. Patient requlatory T cells (Treqs) developed 66 proliferated in response to stimulation. Patient regulatory T cells (Tregs) developed
67 normally but aberrantly produced high levels of many T_H cytokines. Single-cell RNA normally but aberrantly produced high levels of many T_H cytokines. Single-cell RNA 68 sequencing revealed largely normal Tregs (albeit mostly memory), but naïve CD4⁺ T
69 cells that were more enriched in genes related to activation, proliferation, metabolism, 69 cells that were more enriched in genes related to activation, proliferation, metabolism,
60 and T_H differentiation. This work describes the immunological phenotype of one of the 70 and T_H differentiation. This work describes the immunological phenotype of one of the
71 first reported cases of germline dominant negative Helios deficiency, expands our 71 first reported cases of germline dominant negative Helios deficiency, expands our
72 understanding of the pathogenesis of AIHA on a single cell level, and provides valuable ⁷²understanding of the pathogenesis of AIHA on a single cell level, and provides valuable 73 insights into Helios function in a variety of lymphocyte subsets.
74

It is made available under a CC-BY-NC-ND 4.0 International license.

⁷⁵**INTRODUCTION**

76 Immunity is tightly regulated to optimize protective responses against pathogens and
77 malignancy while preventing inappropriate responses to otherwise benign antigens. 77 malignancy while preventing inappropriate responses to otherwise benign antigens.
78 Monogenic defects that impair this regulation of inflammation or tolerance result in a 78 Monogenic defects that impair this regulation of inflammation or tolerance result in a
79 Subaroup of the inborn errors of immunity (IEI) called primary immune regulatory 79 subgroup of the inborn errors of immunity (IEI) called primary immune regulatory
80 disorders (PIRD)¹. In contrast to classic IEIs, which typically manifest as unusually 80 disorders (PIRD)¹. In contrast to classic IEIs, which typically manifest as unusually
81 severe or recurrent infections, PIRDs predominantly present with immune-mediated severe or recurrent infections, PIRDs predominantly present with immune-mediated 82 pathology, including autoimmunity, lymphoproliferation, malignancy, autoinflammation,
83 and atopy, with susceptibility to infections being a less pronounced aspect of these 83 and atopy, with susceptibility to infections being a less pronounced aspect of these
84 disorders². $disorders²$.

85 Immune dysregulation can lead to a variety of hematologic manifestations and
86 cytopenias³. A classic example is autoimmune hemolytic anemia (AIHA) caused by cytopenias³. A classic example is autoimmune hemolytic anemia (AIHA) caused by 87 immune-mediated destruction of erythrocytes⁴. AIHA can be idiopathic (primary) or
88 secondary and is classified as warm or cold (cold agglutinin disease [CAD], paroxysmal 88 secondary and is classified as warm or cold (cold agglutinin disease [CAD], paroxysmal
89 cold hemoglobinuria) depending on autoantibody behaviour at different thermal ranges, 89 cold hemoglobinuria) depending on autoantibody behaviour at different thermal ranges,
90 vhich is important for determining appropriate treatment regimens⁵. Most cases of AIHA 90 which is important for determining appropriate treatment regimens⁵. Most cases of AIHA
91 are considered idiopathic (~60%)⁶, while secondary causes can include IEIs/PIRDs, 91 are considered idiopathic (~60%)⁶, while secondary causes can include IEIs/PIRDs,
92 malignancy, bacterial/viral infections, and drugs⁴. As such, the etiology and 92 malignancy, bacterial/viral infections, and drugs⁴. As such, the etiology and
93 pathogenesisof AIHA remainsincompletely understood. pathogenesis of AIHA remains incompletely understood.

94 In the past 2 years, human germline variants in a family of transcription factors called
95 the IKAROS zinc finger (IKZF) family have been linked to immunodeficiency and 95 the IKAROS zinc finger (IKZF) family have been linked to immunodeficiency and
96 cvtopenias⁷⁻¹⁰, Notably, loss-of-function (LOF) variants in *IKZF2* (Helios) were recently cytopenias⁷⁻¹⁰. Notably, loss-of-function (LOF) variants in *IKZF2* (Helios) were recently 97 associated with combined immunodeficiency (CID) and/or immune dysregulation,
98 including immune thrombocytopenia (ITP), Evan's syndrome, and systemic lupus 98 including immune thrombocytopenia (ITP), Evan's syndrome, and systemic lupus
99 erythematosus⁷⁻⁹. *IKZF2* is highly expressed in hematopoietic stem/progenitor cells, T erythematosus⁷⁻⁹. *IKZF2* is highly expressed in hematopoietic stem/progenitor cells, T
100 cells, including activated CD4⁺/CD8⁺ T cells, mucosa-associated invariant T (MAIT) 100 cells, including activated CD4⁺/CD8⁺ T cells, mucosa-associated invariant T (MAIT) cells, regulatory T cells (Tregs), and natural killer (NK) cells¹¹⁻¹⁶. As Tregs are among
102. the highest *IKZF2* expressors, most studies have focused on the role of Helios in Treg 102 the highest *IKZF2* expressors, most studies have focused on the role of Helios in Treg
103 development and function¹⁷⁻²⁷. In mice, Helios is critical for Treg identity, survival, and development and function¹⁷⁻²⁷. In mice, Helios is critical for Treg identity, survival, and 104 stability, but is seemingly dispensable in mice and humans for suppressive function^{20,27}.

It is made available under a CC-BY-NC-ND 4.0 International license.

105 Nevertheless, both *IKZF2^{-/-}* and Treg-specific *IKZF2^{-/-}* mice develop progressive
106 autoimmune disease associated with activated CD4⁺/CD8⁺ T cells, increased T follicular 106 autoimmune disease associated with activated CD4⁺/CD8⁺ T cells, increased T follicular 107 helper (T_{FH}) and germinal center (GC) B cell numbers, autoantibody production, and
108 increased proinflammatory cytokine production^{19,20,28}. The role of *IKZF2* in other increased proinflammatory cytokine production^{19,20,28}. The role of *IKZF2* in other
109 components of the human immune system (e.g. NK cells) is beginning to be better 109 components of the human immune system (e.g. NK cells) is beginning to be better
110 defined through the identification of humans with germline IKZF2 variants⁷⁻¹⁰. defined through the identification of humans with germline *IKZF2* variants⁷⁻¹⁰.

111 Here, we report a detailed immunological and mechanistic workup of the first reported
112 case of germline heterozygous dominant negative (DN) IKZF2 disorder in a young girl 112 case of germline heterozygous dominant negative (DN) *IKZF2* disorder in a young girl
113 we recently described¹⁰. This patient was found to have a novel genetic syndrome we recently described¹⁰. This patient was found to have a novel genetic syndrome
114. comprising Immunodysregulation. Craniofacial anomalies. Hearing impairment. Athelia. 114 comprising Immunodysregulation, Craniofacial anomalies, Hearing impairment, Athelia,
115 and Developmental delay (or ICHAD syndrome). We report a comprehensive 115 and Developmental delay (or ICHAD syndrome). We report a comprehensive
116 mechanistic immune evaluation of this patient which revealed significant developmental mechanistic immune evaluation of this patient which revealed significant developmental and functional defects in NK and naïve $CD4^+$ T cells and marked immune activation as
118 the likely cause of immune dysregulation. Informed by our improved appreciation of the 118 the likely cause of immune dysregulation. Informed by our improved appreciation of the
119 human phenotype caused by germline IKZF2 variants, we suggest that germline 119 human phenotype caused by germline IKZF2 variants, we suggest that germline
120 heterozygous dominant negative IKZF2 variants should now be considered in the 120 heterozygous dominant negative *IKZF2* variants should now be considered in the 121
121 differential diagnosis of patients with AIHA and PIRD. differential diagnosis of patients with AIHA and PIRD.

122

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

¹²³**METHODS**

124 **Study participants and consent**
125 All study participants and/or their

-
- 125 All study participants and/or their parents/guardians provided written informed consent.
126 Research study protocols (H18-02853, H18-02912, H15-00092) were approved by The 126 Research study protocols (H18-02853, H18-02912, H15-00092) were approved by The
127 Universitv of British Columbia Clinical Research Ethics Board.
- University of British Columbia Clinical Research Ethics Board.

¹²⁸**Cell isolation, culture, and immortalization**

129 Peripheral blood mononuclear cells (PBMCs) were isolated from all study participants
130 by standard Ficoll-Paque (GE Healthcare) density centrifugation as previously 130 by standard Ficoll-Paque (GE Healthcare) density centrifugation as previously
131 described²⁹. Lymphoblastoid cell lines (LCLs) were derived by standard EBV described²⁹. Lymphoblastoid cell lines (LCLs) were derived by standard EBV 132 transformation as previously described²⁹ (**Supplement**).

¹³³**Plasmid generation and cloning**

¹³⁴WT *IZKF2*, p.Gly136_Ser191dup *IKZF2*, pIL2-Luc2 plasmids were generated by 135 introducing restriction sites into cDNA or genomic DNA by PCR and cloning into
136 pCMV6-XL4-3xFLAG and p.GL4.14 firefly luciferase gene reporter (Promega) vectors, pCMV6-XL4-3xFLAG and p.GL4.14 firefly luciferase gene reporter (Promega) vectors, 137 respectively (**Supplement**).

¹³⁸**Transient transfections**

139 HEK293 cells were transfected with empty vector (EV), WT, p.Gly136_Ser191dup, or
140 varying ratios of WT/p.Gly136 Ser191dup IKZF2 expression plasmids by Lipofectamine 140 varying ratios of WT/p.Gly136_Ser191dup *IKZF2* expression plasmids by Lipofectamine
141 3000 (ThermoFisher) transfection (**Supplement**). Transfected cells were then ¹⁴¹3000 (ThermoFisher) transfection (**Supplement**). Transfected cells were then 142 processed for immunoblotting or immunofluorescence. For luciferase assays, cells were
143 additionally transfected with pIL2-Luc2 and Renilla luciferase (R-Luc) plasmids then additionally transfected with pIL2-Luc2 and Renilla luciferase (R-Luc) plasmids then ¹⁴⁴processed with a Dual-Glo Luciferase Assay Kit (#E2920, Promega) (**Supplement**).

¹⁴⁵**Immunoblotting**

146 Helios protein detection was accomplished in LCLs and transfected HEK293 cells by 147 standard immunoblotting as previously described²⁹ (**Supplement**).

¹⁴⁸**Immunofluorescence**

149 12mm coverslips were sterilized, HEK293 cells were seeded on top in 6-well plates,
150 allowed to attach for 24h, then transfected as above. Transfected cells were fixed, allowed to attach for 24h, then transfected as above. Transfected cells were fixed,

- 151 permeabilized, and stained for Helios, DAPI, and F-actin before mounting and imaging
152 on a Leica SP5 II Laser Scanning Confocal Microscope (Leica Microsystems GmbH)
- 152 on a Leica SP5 II Laser Scanning Confocal Microscope (Leica Microsystems GmbH)
153 (Supplement).
- ¹⁵³(**Supplement**).

¹⁵⁴**Immunophenotyping**

Immunophenotyping and intracellular cytokine was performed as previously described³⁰.
156. Briefly, PBMCs were stimulated with PMA and ionomycin (P/I) in the presence of 156 Briefly, PBMCs were stimulated with PMA and ionomycin (P/I) in the presence of
157 GolgiStop (#554724, BD Biosciences), stained with antibody panels 1-4 (**Supplemental** 157 GolgiStop (#554724, BD Biosciences), stained with antibody panels 1-4 (**Supplemental** 158 Table 5) using the eBioscience Foxp3 Transcription Factor Staining Buffer Set (#00-**Table 5**) using the eBioscience Foxp3 Transcription Factor Staining Buffer Set (#00-159 5523-00, Invitrogen, ThermoFisher), acquired on a FACSymphony flow cytometer, and
160 analyzed using FlowJo (both BD Biosciences) (**Supplement**). analyzed using FlowJo (both BD Biosciences) (**Supplement**).

¹⁶¹**Proliferation assays**

162 PBMCs were seeded at varying concentrations, labelled with Cell Proliferation Dye
163 (CPD) eF450 (#65-0842-85, Invitrogen, ThermoFisher) and stimulated with anti-163 (CPD) eF450 (#65-0842-85, Invitrogen, ThermoFisher) and stimulated with anti-164 CD3/CD28-coated Dynabeads (#11141D, Human T-Expander, Gibco, ThermoFisher)
165 for four days. Cells were stained with antibody panel 6 (**Supplemental Table 5**) and 165 for four days. Cells were stained with antibody panel 6 (**Supplemental Table 5**) and
166 acquired on a CytoFLEX (Beckman Coulter) and analyzed using FlowJo (**Supplement**). acquired on a CytoFLEX (Beckman Coulter) and analyzed using FlowJo (**Supplement**).

¹⁶⁷**T cell suppression assays**

168 Treg suppression of $CD3^+$ T cell proliferation was assessed as previously described²⁷. Briefly, patient and control PBMCs were enriched for CD4⁺ T cells, sorted using panel 7
170 (**Supplemental Table 5**) for Tregs and Tconvs, expanded with IL-2 and irradiated ¹⁷⁰(**Supplemental Table 5**) for Tregs and Tconvs, expanded with IL-2 and irradiated 171 mouse L cells for seven days, then cocultured with various ratios of CPD-labelled anti-
172 CD3/CD28 Dynabead-stimulated enriched CD3⁺ T responder (Tresp) cells for four days. $CD3/CD28$ Dynabead-stimulated enriched $CD3⁺$ T responder (Tresp) cells for four days. 173 Percent suppression of CD4⁺ and CD8⁺ T cell proliferation was calculated using division ¹⁷⁴index (DI): (1 - [DI of sample/DI of positive control]) x 100% (**Supplement**).

¹⁷⁵**Quantification of cytokine production**

176 Supernatants were collected from PBMCs stimulated for proliferation, cocultured Tregs
177 and Tresp for T cell suppression assays, and stimulated Tregs and Tconvs alone. and Tresp for T cell suppression assays, and stimulated Tregs and Tconvs alone. 178 Cytokine concentrations were measured by LEGENDplex Human Th Cytokine Panel
179 12-plex (#741027, BioLegend) on a CytoFLEX (Beckman Coulter) and analyzed with 12-plex (#741027, BioLegend) on a CytoFLEX (Beckman Coulter) and analyzed with

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

180 Qognit software (BioLegend) according to manufacturer's recommendations 181 (Supplement). ¹⁸¹(**Supplement**).

¹⁸²**TSDR methylation**

183 Genomic DNA was isolated from expanded Tregs and Tconvs, bisulfite converted with
184 an EZ DNA Methylation-Direct Kit (Zymo Research), PCR amplified, and EZ DNA Methylation-Direct Kit (Zymo Research), PCR amplified, 185 pyrosequenced using a PyroMark Q96 MD (Qiagen) as previously described²⁷
186 (**Supplement**). ¹⁸⁶(**Supplement**).

¹⁸⁷**Single-cell RNA sequencing**

188 Single-cell RNA sequencing was performed on unstimulated and 4h P/I-stimulated
189 sorted Tregs and Tconv from P1 and two age-matched/sex-matched controls using the 189 sorted Tregs and Tconv from P1 and two age-matched/sex-matched controls using the
190 BD Rhapsody Single Cell platform (BD Biosciences) according to manufacturer's 190 BD Rhapsody Single Cell platform (BD Biosciences) according to manufacturer's recommendations and analyzed as previously described³⁰ (**Supplement**). Raw data are recommendations and analyzed as previously described³⁰ (**Supplement**). Raw data are
192 deposited on Gene Expression Omnibus. deposited on Gene Expression Omnibus.

It is made available under a CC-BY-NC-ND 4.0 International license.

¹⁹⁴**RESULTS**

¹⁹⁵**Clinical case presentation**

196 The index patient (P1) is a 5-10-year-old girl born to non-consanguineous parents
197 (Figure 1A) who presented with syndromic features of developmental abnormalities and (Figure 1A) who presented with syndromic features of developmental abnormalities and 198 immune dysregulation. Family history is unremarkable. She has profound bilateral
199 sensorineural hearing loss, microcephaly, mild developmental delay, cleft palate, 199 sensorineural hearing loss, microcephaly, mild developmental delay, cleft palate,
200 hypotonia, athelia, and dysmorphic facies (detailed in¹⁰). Consistent with underlying 200 hypotonia, athelia, and dysmorphic facies (detailed in¹⁰). Consistent with underlying
201 immune dysregulation, she has suffered from chronic anemia beginning at two months 201 immune dysregulation, she has suffered from chronic anemia beginning at two months
202 of age, which at times required hospitalization and red blood cell transfusions (Figure 202 of age, which at times required hospitalization and red blood cell transfusions (**Figure** 203
203 **1B-I**). She also had severe atopic dermatitis beginning at ten months of age affecting 203 **1B-I**). She also had severe atopic dermatitis beginning at ten months of age affecting
204 the face, arms, legs, and trunk. Her skin inflammation was initially refractory to optimal 204 the face, arms, legs, and trunk. Her skin inflammation was initially refractory to optimal
205 heredical therapy (i.e. topical corticosteroids, emollients, bleach baths), but has become 205 medical therapy (i.e. topical corticosteroids, emollients, bleach baths), but has become
206 more manageable with age. The patient also experienced frequent upper respiratory 206 more manageable with age. The patient also experienced frequent upper respiratory
207 tract infections, which reduced in frequency following initiation of monthly intravenous 207 tract infections, which reduced in frequency following initiation of monthly intravenous
208 immunoglobulin (IVIG) replacement therapy. Laboratory and hematologic evaluation 208 immunoglobulin (IVIG) replacement therapy. Laboratory and hematologic evaluation
209 revealed chronically positive direct antiglobulin tests (DAT) initially consistent with a 209 revealed chronically positive direct antiglobulin tests (DAT) initially consistent with a
210 mixed (cold>warm) AIHA phenotype, which progressed to a predominantly warm AIHA mixed (cold>warm) AIHA phenotype, which progressed to a predominantly warm AIHA 211 phenotype with age without overt hemolysis. Other notable hematological features
212 included a normocellular bone marrow with scattered hemophagocytic macrophages, no 212 included a normocellular bone marrow with scattered hemophagocytic macrophages, no
213 morphological evidence for dysplastic cells or a progressive marrow disorder, 213 morphological evidence for dysplastic cells or a progressive marrow disorder,
214 lymphopenia, and elevated IgE (**Table 1**). Red cells did not carry any hemoglobin 214 Iymphopenia, and elevated IgE (**Table 1**). Red cells did not carry any hemoglobin
215 variants, although non-specific poikilocytosis and rouleaux formation were noted. variants, although non-specific poikilocytosis and rouleaux formation were noted.

Given the unique constellation of features, P1 underwent trio WGS (detailed in¹⁰). This
217 Frevealed a novel *de novo* germline heterozygous structural variant affecting *IKAROS* 217 revealed a novel *de novo* germline heterozygous structural variant affecting *IKAROS*
218 *zinc finger 2 (IKZF2*) encoding Helios (NM 016260.3:c.406+540 574+13477dup; ²¹⁸*zinc finger 2* (*IKZF2*) encoding Helios (NM_016260.3:c.406+540_574+13477dup; 219 NP_057344.2:p.Gly136_Ser191dup) (**Figure 1J-K**). The variant results in intron 5 at
220 chr2:213900960 being joined to intron 6 chr2:213921017 (GRCh37) with a 2 bp GT 220 chr2:213900960 being joined to intron 6 chr2:213921017 (GRCh37) with a 2 bp GT
221 insertion in between. This leads to tandem duplication of exon 5 (~20kb duplication 221 insertion in between. This leads to tandem duplication of exon 5 (~20kb duplication
222 spanning exon 5 and parts of flanking introns), corresponding to tandem duplication of 222 spanning exon 5 and parts of flanking introns), corresponding to tandem duplication of 223 zinc fingers 2 and 3 of Helios (Figure 1K). zinc fingers 2 and 3 of Helios (**Figure 1K**).

²²⁴**Characterization of the impact of the p.Gly136_Ser191dup Helios variant on** ²²⁵**protein expression and localization**

226 The p.Gly136_Ser191dup Helios variant created a higher molecular weight Helios
227 protein (as anticipated with a ~13kDa 56 amino acid duplication) detected in both 227 protein (as anticipated with a ~13kDa 56 amino acid duplication) detected in both
228 transfected HEK293 cells and primary patient-derived LCLs (**Figure 2A, C** and detailed 228 transfected HEK293 cells and primary patient-derived LCLs (**Figure 2A, C** and detailed
229 in¹⁰). Total Helios protein expression was reduced overall in both transfected HEK293 229 in¹⁰). Total Helios protein expression was reduced overall in both transfected HEK293
230 (Figure 2A-B) and patient-derived LCLs (Figure 2C-E), likely because the variant ²³⁰(**Figure 2A-B**) and patient-derived LCLs (**Figure 2C-E**), likely because the variant 231 protein was less stable. As a TF, Helios localizes to the nucleus to regulate
232 transcription¹². We transfected HEK293 cells with WT or p.Gly136 Ser191dup IKZF2 232 transcription¹². We transfected HEK293 cells with WT or p.Gly136_Ser191dup *IKZF*2
233 alone, or increasing quantities of p.Gly136 Ser191dup together with WT *IKZF2* (**Fiqure** 233 alone, or increasing quantities of p.Gly136_Ser191dup together with WT *IKZF2* (Figure
234 **2F**) to assess protein expression by immunofluorescence. The variant protein was 234 **2F**) to assess protein expression by immunofluorescence. The variant protein was
235 indistinguishable from WT protein in nuclear localization, nor did it affect the nuclear 235 indistinguishable from WT protein in nuclear localization, nor did it affect the nuclear
236 localization of WT protein. localization of WT protein.

²³⁷**p.Gly136_Val192dup Helios acts through dominant interference**

238 Helios has previously been shown to bind the *IL2* promoter to silence IL-2 production in
239 Tregs³². We therefore cloned the human *IL2* promoter (-580 bp to +57 bp) into a firefly 239 Tregs³². We therefore cloned the human *IL2* promoter (-580 bp to +57 bp) into a firefly
240 Iuciferase gene reporter vector and cotransfected this with Renilla luciferase, WT or luciferase gene reporter vector and cotransfected this with Renilla luciferase, WT or 241 p.Gly136_Ser191dup *IKZF*2 alone, or p.Gly136_Ser191dup together with WT (**Figure**
242 **2G** and detailed in¹⁰). As expected. WT *IKZF*2 stronaly repressed *IL2* promoter activity. 242 **2G** and detailed in¹⁰). As expected, WT *IKZF2* strongly repressed *IL2* promoter activity.
243 However, p.Gly136 Val192dup not only showed impaired repression on its own, but 243 However, p.Gly136_Val192dup not only showed impaired repression on its own, but
244 Significantly interfered with WT IKZF2-mediated IL2 repression (Fiqure 2G). This DN ²⁴⁴significantly interfered with WT *IKZF2*-mediated *IL2* repression (**Figure 2G**). This DN 245 effect was dose-dependent, with increasing quantities of p.Gly136_Ser191dup
246 transfected correlating with more impaired WT *IKZF2*-dependent *IL2* repression 246 transfected correlating with more impaired WT *IKZF*2-dependent *IL2* repression
247 (r²=0.94, p<0.0005) (Figure 2H and detailed in¹⁰). 247 (r²=0.94, p<0.0005) (**Figure 2H** and detailed in¹⁰).

**Patient lymphocyte phenotyping reveals NK cell lymphocytosis and CD3⁺ T cell
249 Iymphopenia** ²⁴⁹**lymphopenia**

250 Helios is highly expressed in CD3⁺ T cells and NK cells¹¹, both of which are known to be 251 dysregulated in AIHA⁴. We profiled the frequencies of $CD3^+$ T, $CD3^{\circ}CD56^+$ NK, and 252 CD3⁺CD56⁺ NKT cells as well as Helios expression from P1 (n=5 independent blood 253 draws) and a cohort of adult $(n=8)$ and age-matched controls $(n=11)$. P1 had

It is made available under a CC-BY-NC-ND 4.0 International license.

254 significantly reduced frequencies of CD3⁺ T (**Figure 3A-B**), markedly elevated NK
255 (**Figure 3A,C**), and modestly elevated NKT (**Figure 3A,D**) cells, all of which were 255 (Figure 3A,C), and modestly elevated NKT (Figure 3A,D) cells, all of which were
256 Helios-deficient (Figure 3E-H). ²⁵⁶Helios-deficient (**Figure 3E-H**).

²⁵⁷**P1 NK cells are phenotypically immature and functionally abnormal**

258 Given the intriguing NK cell lymphocytosis, we set out to define the developmental and
259 functional status of P1 NK cells by assessing the expression of CD56, maturation 259 functional status of P1 NK cells by assessing the expression of CD56, maturation
260 (CD27, CD57, CD94), adhesion (CD16), and activation (CD8, CD25) markers³³⁻³⁵ on P1 (CD27, CD57, CD94), adhesion (CD16), and activation (CD8, CD25) markers³³⁻³⁵ on P1
261 NK cells compared to controls. The relative abundance of CD56^{dim} and CD56^{bright} NK 261 NK cells compared to controls. The relative abundance of CD56^{dim} and CD56^{bright} NK
262 cell populations was normal (**Figure 3I-J**), although on histograms, the patient lacked a 262 cell populations was normal (**Figure 3I-J**), although on histograms, the patient lacked a
263 clear CD56^{bright} population (**Figure S1A**), Strikingly, all maturation markers assessed 263 clear CD56^{bright} population (**Figure S1A**). Strikingly, all maturation markers assessed
264 vwere dysregulated in P1, including significantly reduced CD16⁺ (Figure 3K, Figure were dysregulated in P1, including significantly reduced CD16⁺ (Figure 3K, Figure **38**, eigure **3M**, Figure **3M**, Fi 265 **S1B**) and CD57⁺ (Figure 3L, Figure S1C), but elevated CD27⁺ (Figure 3M, Figure 266 **S1D**) and CD94⁺ (**Figure 3N, Figure S1E**) NK cells. Similarly, the frequency of CD8⁺ 267 NK cells were significantly reduced in the patient both at baseline and in response to
268 stimulation (Figure 3O, Figure S1F), while CD25⁺ NK cells (Figure 3P, Figure S1G) 268 stimulation (**Figure 3O, Figure S1F**), while CD25⁺ NK cells (**Figure 3P, Figure S1G**)
269 were normal. This abnormal distribution of markers disproportionately affected CD56^{dim} 269 were normal. This abnormal distribution of markers disproportionately affected CD56^{dim}
270 NK cells more than CD56^{bright} NK cells, although Helios was reduced in both populations 270 NK cells more than CD56^{bright} NK cells, although Helios was reduced in both populations
271 (Figure S1H-N). Taken together, patient NK cells are skewed towards an immature ²⁷¹(**Figure S1H-N**). Taken together, patient NK cells are skewed towards an immature 272 phenotype.

273 As NK cells mediate their effector functions through the release of proinflammatory
274 cytokines and cytolysis³³, we studied whether these roles were affected in P1. In cytokines and cytolysis³³, we studied whether these roles were affected in P1. In 275 response to stimulation, P1 had significantly elevated IFN-γ⁺ NK cells (**Figure 3Q**, **Figure S1O**), but comparable TNF-α⁺ NK cells (**Figure 3R, Figure S1P**). Similarly, P1 277 NK cells expressed significantly less granzyme B (**Figure 3S**) and perforin (**Figure 3T**), 278 with this effect being more pronounced in CD56^{dim} NK cells (Figure S1Q-R). These 278 with this effect being more pronounced in CD56^{dim} NK cells (**Figure S1Q-R**). These
279 defects were confirmed in multidimensional space when we clustered live CD3⁻CD56⁺ 279 defects were confirmed in multidimensional space when we clustered live CD3CD56⁺ 280 NK cells from P1 and adult and pediatric controls on CD16, CD27, CD57, CD94, Helios, 281 perforin, granzyme B, IFN-γ, and TNF- α at baseline and in response to stimulation ²⁸²(**Figure 3U-V**, **Figure S1S**).

It is made available under a CC-BY-NC-ND 4.0 International license.

Patient CD8⁺ T cells are significantly reduced, have high PD-1 expression, and are 284 potent proinflammatory cytokine producers ²⁸⁴**potent proinflammatory cytokine producers**

285 As CD8⁺ T cells are frequently enriched in autoimmune disease³⁶ and can be clonally 286 expanded in AIHA³⁷, we assessed the frequency of CD8⁺ T cells and subsets and their
287 Helios expression. P1 had profound CD8⁺ T cell lymphopenia (**Figure 4A-B**), 287 Helios expression. P1 had profound CD8⁺ T cell lymphopenia (**Figure 4A-B**),
288 significantly elevated frequencies of central memory (CM) with a concurrent reduction in 288 significantly elevated frequencies of central memory (CM) with a concurrent reduction in
289 naïve subsets, while effector memory (EM) and TEMRA subsets were normal (Figure 289 naïve subsets, while effector memory (EM) and TEMRA subsets were normal (**Figure** 289 naïve subsets, while effector memory (EM) and **4C-G**). Importantly, all P1 CD8⁺ T cell subsets were Helios-deficient (Figure 4H-I) **4C-G**). Importantly, all P1 CD8⁺ T cell subsets were Helios-deficient (**Figure 4H-I**).

291 PD-1 is a critical inhibitory receptor that is upregulated in activated, memory, or
292 exhausted T cells to restrain effector functions³⁸. We therefore assessed PD-1 exhausted T cells to restrain effector functions³⁸. We therefore assessed PD-1
293. expression and proinflammatory cytokine production in P1 CD8⁺ T cells. In line with expression and proinflammatory cytokine production in P1 CD8+ ²⁹³T cells. In line with 294 elevated CD8 CM, we discovered significantly more PD-1 expression on P1 CD8⁺ T
295 cells (**Figure 4J-K**). These T cells are likely not exhausted as both naïve and total 295 cells (**Figure 4J-K**). These T cells are likely not exhausted as both naïve and total
296 memory CD8⁺ T cells produced significantly more TNF- α (**Figure 4L-N**) and IFN- γ of the memory CD8⁺ T cells produced significantly more TNF-α (**Figure 4L-N**) and IFN-γ
297 (**Figure 4O-Q**) than controls, while CD8⁺ T cell proliferation was comparable to controls 297 (**Figure 4O-Q**) than controls, while CD8⁺ T cell proliferation was comparable to controls
298 (**Figure 4R-S**). ²⁹⁸(**Figure 4R-S**).

**P1 CD19⁺ B cells show largely normal development but increased TNF-α
300 production** ³⁰⁰**production**

301 Although Ikaros and Aiolos are both critical for B cell differentiation³⁹, the role of Helios 302 in these cells is less clear. Helios silencing is thought to maintain B cell function as
303 ectopic expression leads to B cell hyperresponsiveness and lymphomagenesis⁴⁰. We 303 ectopic expression leads to B cell hyperresponsiveness and lymphomagenesis⁴⁰. We
304 therefore studied the development and function of P1 B cells. In general. B cell 304 therefore studied the development and function of P1 B cells. In general, B cell
305 development was largely normal, with intact total CD19⁺ (Figure S2A-B), naïve (Figure development was largely normal, with intact total CD19⁺ (Figure S2A-B), naïve (Figure ³⁰⁶**S2C, D**), switched memory [SM] (**Figure S2C, F**), and plasmablasts (**Figure S2I-J**). 307 However, we did observe significantly increased non-switched memory [NSM] (**Figure**
308 **S2C, E**) and decreased transitional B cells (**Figure S2G-H**), while Helios was lowly ³⁰⁸**S2C, E**) and decreased transitional B cells (**Figure S2G-H**), while Helios was lowly ³⁰⁹expressed in all B cell populations from both P1 and controls (**Figure S2K-L**). In 310 response to stimulation, patient B cells produced significantly more TNF-α than controls
311 **(Figure S2M**). This applied to NSM (**Figure S2N**), SM (**Figure S2O**), and naïve (**Figure** ³¹¹(**Figure S2M**). This applied to NSM (**Figure S2N**), SM (**Figure S2O**), and naïve (**Figure S2P**) subsets.

It is made available under a CC-BY-NC-ND 4.0 International license.

P1 CD4⁺ T cells are more mature

314 CD4⁺ T helper (T_H) cells and their subsets are critical for both protective antimicrobial
315 immunity and driving pathological states such as autoimmunity and atopic disease⁴¹. 315 immunity and driving pathological states such as autoimmunity and atopic disease⁴¹.
316 We therefore enumerated the frequency of total CD4⁺ T cells and subsets and Helios 316 We therefore enumerated the frequency of total CD4⁺ T cells and subsets and Helios
317 expression. P1 CD4⁺ T cells were modestly elevated (**Figure 5A**) in line with CD8⁺ T 317 expression. P1 CD4⁺ T cells were modestly elevated (Figure 5A) in line with CD8⁺ T 318 lymphopenia. We also found similar subset distributions to P1 CD8⁺ T cells, including
319 significantly increased CD4⁺ CM (**Figure 5B, D**), with an associated reduction in naïve 319 significantly increased CD4⁺ CM (**Figure 5B, D**), with an associated reduction in naïve
320 (**Figure 5B, C**), while EM and TEMRA subsets (**Figure 5E-F**) were normal. Helios 320 (**Figure 5B, C**), while EM and TEMRA subsets (**Figure 5E-F**) were normal. Helios
321 expression was low in all CD4⁺ subsets (**Figure 5G-H**). expression was low in all CD4⁺ subsets (**Figure 5G-H**).

P1 CD4+ ³²²**T cells are hyperresponsive and exhibit effector phenotypes**

323 In mice, Treg-specific, but not complete knockout, of *Ikzf*2 in mice leads to increased
324 PD-1 expression on CD4⁺ T cells²⁰. Surprisingly, P1 had three-fold higher PD-1⁺ CD4⁺ T 324 PD-1 expression on CD4⁺ T cells²⁰. Surprisingly, P1 had three-fold higher PD-1⁺ CD4⁺ T 325 cells than controls (**Figure 5I-J**), which could signify higher activation status. We thus
326 measured the frequency of T_H subsets and cytokine production. Mirroring our *IL2* 326 measured the frequency of T_H subsets and cytokine production. Mirroring our *IL2*
327 promoter luciferase data (**Figure 2F-G**), we observed a striking increase in IL-2⁺ CD4⁺ T 327 promoter luciferase data (**Figure 2F-G**), we observed a striking increase in IL-2⁺ CD4⁺ T 328 cells in P1 (**Figure 5K-L**). This was not limited to IL-2, as the patient also had
329 significantly increased IFN-γ⁺ and TNF-α⁺ CD4⁺ T cells (**Figure 5M-P**) and most T_H 329 significantly increased IFN-γ⁺ and TNF-α⁺ CD4⁺ T cells (**Figure 5M-P**) and most T_H 330 subsets, including T_H1, T_H2 (**Figure 5Q-S**), T_H9, T_{FH} (**Figure 5T-V**), and T_H17 (**Figure**
331 **S3A-B**). This also held true when we measured T_H cytokines in the supernatant of **S3A-B**). This also held true when we measured T_H cytokines in the supernatant of 332 stimulated PBMCs, where we found markedly elevated concentrations of IL-2, IL-4, IL-5,
333 IL-6, IL-9, IL-13, and TNF-α, even in response to lower bead:cell ratios (**Fiqure 5W,** ³³³IL-6, IL-9, IL-13, and TNF-α, even in response to lower bead:cell ratios (**Figure 5W,** 334 Figure S3C-N). Surprisingly, we observed marked impairment in secreted IL-22 levels
335 (Figure S3L). In keeping with this picture of hyperactive CD4⁺ T cells, P1 CD4⁺ T cells 335 (Figure S3L). In keeping with this picture of hyperactive CD4⁺ T cells, P1 CD4⁺ T cells 336 more readily proliferated in response to stimulation than controls (97.1% divided in ³³⁷patient vs. 54.5% in control) (**Figure 5X-Y**).

³³⁸**P1 has normal Treg frequencies and TSDR methylation**

339 ~70-80% of Tregs express Helios and at least in mice, this is thought to be important for
340 requlating Treg identity and function⁴². As Tregs are critical mediators of 340 regulating Treg identity and function⁴². As Tregs are critical mediators of
341 tolerance/homeostasis and their dysfunction is associated with allergic and autoimmune 341 tolerance/homeostasis and their dysfunction is associated with allergic and autoimmune
342 disease⁴³, we enumerated their frequency and Helios expression in P1. P1 had normal disease⁴³, we enumerated their frequency and Helios expression in P1. P1 had normal

It is made available under a CC-BY-NC-ND 4.0 International license.

343 frequencies of CD3⁺CD4⁺CD8⁻CD25⁺CD127^{lo}FOXP3⁺ Tregs (**Figure 6A, Figure S4A**), ³⁴⁴but significantly reduced Helios expression (**Figure 6B-C**).

345 Since methylation of the Treg-specific demethylated region (TSDR) in the *FOXP3* gene
346 is important for maintaining stable FOXP3 expression and Treg suppressive 346 is important for maintaining stable FOXP3 expression and Treg suppressive
347 function^{44,45}, we quantified expanded P1 Treg TSDR methylation and FOXP3 347 function^{44,45}, we quantified expanded P1 Treg TSDR methylation and FOXP3
348 expression in comparison to Tregs from healthy female controls. TSDR methylation was 348 expression in comparison to Tregs from healthy female controls. TSDR methylation was
349 normal (**Figure 6D**), although the average methylation trended to higher in P1 (**Figure** 349 normal (**Figure 6D**), although the average methylation trended to higher in P1 (**Figure** 350 **S4B**). Ex vivo P1 Tregs had significantly higher FOXP3 expression than controls, likely 350 **S4B**). E*x vivo* P1 Tregs had significantly higher FOXP3 expression than controls, likely
351 reflecting a higher state of activation (**Figure 6E**). ³⁵¹reflecting a higher state of activation (**Figure 6E**).

P1 Tregs are predominantly PD-1⁺ and are potent T_H cytokine producers

353 Given the striking increase in PD-1⁺ CD4+ (Figure 5I-J) and CD8⁺ (Figure 4J-K) T cells 354 in P1, we assessed PD-1 expression in P1 *ex vivo* Tregs. Similarly, P1 had significantly
355 more PD-1⁺ Tregs(~80%) than controls(~40%) (**Figure 6F, Figure S4C**). Helios more PD-1⁺ Tregs (~80%) than controls (~40%) (**Figure 6F, Figure S4C**). Helios 356 genetic or pharmacological targeting in Tregs leads to elevated IL-2³², IFN-γ, and IL-
357 17A^{19,20,28,46} and effector T_H cell signatures⁴⁷. We thus studied T_H cytokine production in 357 17A^{19,20,28,46} and effector T_H cell signatures⁴⁷. We thus studied T_H cytokine production in
358 ex vivo Tregs and discovered significantly elevated IL-2⁺ Tregs in P1 (Figure 6G-H), 358 *ex vivo* Tregs and discovered significantly elevated IL-2⁺ Tregs in P1 **(Figure 6G-H)**,
359 confirming our IL2 luciferase data (**Figure 2F-G**). P1 also had a striking increase in IL-4⁺ confirming our *IL2* luciferase data (**Figure 2F-G**). P1 also had a striking increase in IL-4⁺
360 (**Figure 6I-J**), IFN-γ⁺ (**Figure 6I, K**), IL-9⁺ (**Figure 6L, Figure S4D**), IL-21⁺ (**Figure 6M,** 360 (Figure 6I-J), IFN-γ⁺ (Figure 6I, K), IL-9⁺ (Figure 6L, Figure S4D), IL-21⁺ (Figure 6M, **Figure S4D**), and TNF-α⁺ (**Figure 6N-O**) Tregs. Expanded P1 Tregs also produced
362 higher concentrations of IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, and IL-17F (**Figure 6P,** ³⁶²higher concentrations of IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, and IL-17F (**Figure 6P,** ³⁶³**Figure S4C-N**).

³⁶⁴**P1 Tregs have impaired suppressive function are not intrinsically resistant to** ³⁶⁵**being suppressed**

366 The abnormal cytokine production in P1 Tregs prompted us to investigate their ability to
367 Suppress T responder (Tresp) proliferation and cytokine production. We cocultured 367 suppress T responder (Tresp) proliferation and cytokine production. We cocultured
368 expanded P1 and control Tregs at different ratios with stimulated control CD3⁺ Tresp. expanded P1 and control Tregs at different ratios with stimulated control CD3⁺ Tresp.
369 TWe discovered no significant differences between patient or control Treg-mediated 369 We discovered no significant differences between patient or control Treg-mediated
370 suppression of CD4⁺ (Figure 6Q) or CD8⁺ (Figure 6R) T cell proliferation, although 370 suppression of CD4⁺ (Figure 6Q) or CD8⁺ (Figure 6R) T cell proliferation, although 371 suppression trended to lower in the 1:2.5 and 1:5 Treg:CD3 T cell ratios.

It is made available under a CC-BY-NC-ND 4.0 International license.

372 An intrinsic resistance to Treg-mediated suppression could also contribute to the
373 patient's prominent hyperactivation phenotype. We reversed our setup from above and 373 patient's prominent hyperactivation phenotype. We reversed our setup from above and
374 cocultured control Tregs with P1 CD3⁺ Tresp and measured suppression of T_H 374 cocultured control Tregs with P1 CD3⁺ Tresp and measured suppression of T_H
375 cytokines. P1 T_H cytokine production was effectively suppressed by control Tregs 375 cytokines. P1 T_H cytokine production was effectively suppressed by control Tregs
376 (Figure 6S, Figure S5), excluding an intrinsic defect in susceptibility to suppression. ³⁷⁶(**Figure 6S, Figure S5**), excluding an intrinsic defect in susceptibility to suppression.

³⁷⁷**scRNA-seq reveals a predominantly memory and effector phenotype in P1 Tregs**

378 To assess transcriptomic pathways that could drive the striking patient Treg phenotype,
379 vwe sorted CD4⁺CD25⁺CD127^{lo} Tregs from P1 and two age-matched/sex-matched 379 we sorted CD4⁺CD25⁺CD127^{lo} Tregs from P1 and two age-matched/sex-matched 380 controls (**Figure S6A**). We carried out whole transcriptome single-cell RNA sequencing
381 (scRNA-seq) on Tregs from P1 (n=295 cells) and controls (n=331 cells) and performed 381 (scRNA-seq) on Tregs from P1 (n=295 cells) and controls (n=331 cells) and performed
382 dimensionality reduction using the uniform manifold approximation and projection 382 dimensionality reduction using the uniform manifold approximation and projection
383 (UMAP) method⁴⁸. Patient Tregs clustered separately from controls (**Figure 7A**) and (UMAP) method⁴⁸. Patient Tregs clustered separately from controls (Figure 7A) and 384 when cell identity was annotated using the DICE project⁴⁹, they were predominantly 385 Iabelled as memory Treg and T_H subsets (T_H1 T_H2, T_H17, T_{FH}), in line with the activated
386 and aberrant cytokine phenotype observed (**Figure 6F-P**). Similarly, annotation based 386 and aberrant cytokine phenotype observed (**Figure 6F-P**). Similarly, annotation based
387 on CD45RA AbSeq/HLA-DR AbSeq expression to identify CD45RA⁺HLA-DR⁻ naïve, 387 on CD45RA AbSeq/HLA-DR AbSeq expression to identify CD45RA+HLA-DR naïve, 388 CD45RA HLA-DR⁺ activated, and CD45RA HLA-DR⁻ Tregs^{50,51} also found that P1 Tregs were predominantly CD45RA⁻HLA-DR⁺ 389 were predominantly CD45RA⁻HLA-DR⁺ and CD45RA⁻HLA-DR⁻. (Figure 7B). 390 Nevertheless, P1 Treg subsets were transcriptomically similar to control Tregs (**Figure**
391 **7C-E, Figure S6B-D**), except for significantly increased *IL2, PDCD1*, and *CCR4* ³⁹¹**7C-E**, **Figure S6B-D**), except for significantly increased *IL2*, *PDCD1*, and *CCR4* ³⁹²transcript abundance in P1 naïve Tregs (**Figure 7C**), consistent with our flow cytometry ³⁹³data (**Figure 6F-H**).

394 scRNA-seq reveals a predominantly memory and effector phenotype in P1 CD4⁺
395 Tconvs ³⁹⁵**Tconvs**

396 Given the profound CD4 phenotype, we also sorted CD4⁺CD25 CD127⁺ Tconv cells 397 from P1 and two age-matched/sex-matched controls and performed scRNA-seq (P1
398 n=854 cells; control n=1225 cells) (**Figure S7A**). Like Tregs, P1 Tconv clustered 398 n=854 cells; control n=1225 cells) (**Figure S7A**). Like Tregs, P1 Tconv clustered
399 separately from controls and were frequently labelled as T_H subsets (**Figure 7F**) and 399 separately from controls and were frequently labelled as T_H subsets (**Figure 7F**) and 400 CD45RA⁻ memory (**Figure 7G**). When comparing the transcriptome of AbSeq-inferred 400 CD45RA⁻ memory (**Figure 7G**). When comparing the transcriptome of AbSeq-inferred
401 naïve (**Figure 7H, Figure S7E**) and memory (**Figure 7I, Figure S7F**) CD4⁺ Tconv cells naïve (**Figure 7H, Figure S7E**) and memory (**Figure 7I, Figure S7F**) CD4⁺ Tconv cells

It is made available under a CC-BY-NC-ND 4.0 International license.

402 between P1 and controls, we found similar memory, but distinctly different naïve
403 populations. Unstimulated naïve P1 CD4⁺ Tconv cells had significantly higher transcript populations. Unstimulated naïve P1 CD4⁺ Tconv cells had significantly higher transcript
404 abundance of genes related to IL-2 signalling, activation, and migration (IL2RB, CXCR4, ⁴⁰⁴abundance of genes related to IL-2 signalling, activation, and migration (*IL2RB*, *CXCR4*, 405 *PDCD1*, *CCL5*, *JUN*). Stimulated P1 CD4⁺ Tconv cells had significantly higher
406 expression of proinflammatory cytokine/chemokine genes (IL2, IFNG, TNF, CCL4), 406 expression of proinflammatory cytokine/chemokine genes (*IL2*, *IFNG*, *TNF*, *CCL4*),
407 confirming our CD4⁺ phenotyping data (Figure 5K-P). confirming our CD4⁺ phenotyping data (**Figure 5K-P**).

408 P1 CD4⁺ Tconvs are poised for T_H differentiation

409 To study what pathways could be driving naïve CD4⁺ Tconv differences, we carried out 410 gene set enrichment analyses. Unstimulated naïve P1 CD4⁺ Tconv cells were more
411 enriched in pathways related to proliferation, IL-6 signalling, allograft rejection, ⁴¹¹enriched in pathways related to proliferation, IL-6 signalling, allograft rejection, apoptosis, and hypoxia. Further, stimulated patient CD4⁺ Tconv cells showed significant
413 enrichment in proliferation (Myc targets V1/V2), metabolism (glycolysis, 413 enrichment in proliferation (Myc targets V1/V2), metabolism (glycolysis, 414 gluconeogenesis, mTORC1 signaling), Treg survival (IL-2-STAT5), impaired tolerance 415 (allograft rejection), atopy (TSLP pathway), and T_H differentiation (IL-27-/IL-12-/IL-23-
416 mediated signalling events, T_H1, T_H2, T_H17 cell differentiation) pathways (**Figure 7J**). In 416 mediated signalling events, T_H1 , T_H2 , T_H17 cell differentiation) pathways (**Figure 7J**). In
417 line with the primed/poised phenotype of P1 naïve CD4⁺ Tconv cells, we observed 417 line with the primed/poised phenotype of P1 naïve CD4⁺ Tconv cells, we observed
418 significantly increased IL-2⁺ (**Figure 7K-L**), IFN- γ^{\dagger} (**Figure 7M-N**), and TNF- α^{\dagger} (**Figure** Al8 significantly increased IL-2⁺ (Figure 7K-L), IFN-γ⁺ (Figure 7M-N), and TNF-α⁺ (Figure **7O-P**) naïve P1 CD4⁺ T cells, with a similar trend observed in memory.

It is made available under a CC-BY-NC-ND 4.0 International license.

⁴²¹**DISCUSSION**

422 Germline pathogenic variants in *IKZF2* have only been discovered in humans in the
423 past two years. The initial descriptions were of germline heterozygous or homozygous 423 past two years. The initial descriptions were of germline heterozygous or homozygous
424 LOF IKZF2 variants in a total of 13 patients with combined immunodeficiency and/or 424 LOF *IKZF2* variants in a total of 13 patients with combined immunodeficiency and/or
425 immune dysregulation⁷⁻⁹ (summarized in **Figure S7A, Table S3**). Collectively, these a immune dysregulation⁷⁻⁹ (summarized in **Figure S7A, Table S3**). Collectively, these
426 germline LOF *IKZF2* variants were predominantly heterozygous (10/13) and were 426 germline LOF *IKZF2* variants were predominantly heterozygous (10/13) and were
427 mostly associated with evidence of immune dysregulation (10/13) (**Table S4**), including 427 mostly associated with evidence of immune dysregulation (10/13) (**Table S4**), including
428 systemic lupus erythematosus (SLE), hemophagocytic lymphohistiocytosis (HLH), 428 systemic lupus erythematosus (SLE), hemophagocytic lymphohistiocytosis (HLH),
429 idiopathic thrombocytopenic purpura (ITP), and Evan's syndrome. Our group recently 429 idiopathic thrombocytopenic purpura (ITP), and Evan's syndrome. Our group recently
430 expanded this list through the discovery of 2 patients with germline DN IKZF2 variants 430 expanded this list through the discovery of 2 patients with germline DN *IKZF2* variants
431 who presented with ICHAD syndrome¹⁰. Notably the patient carrying the DN pathogenic 431 who presented with ICHAD syndrome¹⁰. Notably the patient carrying the DN pathogenic
432 c.406+540_574+13477dup;p.Gly136_Ser191dup *IKZF2* variant (designated P1) c.406+540_574+13477dup;p.Gly136_Ser191dup *IKZF2* variant 433 experienced the most severe clinical manifestations of immune dysregulation out of all
434 15 patients described to date with pathogenic germline *IKZF2* variants (Figure S7B). P1 ⁴³⁴15 patients described to date with pathogenic germline *IKZF2* variants (**Figure S7B**). P1 435 presented with syndromic developmental features plus significant chronic AIHA and
436 atopic dermatitis, features consistent with classification as a PIRD. Given the profound 436 atopic dermatitis, features consistent with classification as a PIRD. Given the profound
437 immune dysregulation associated with the DN pathogenic 437 immune dysregulation associated with the DN pathogenic 438 c.406+540_574+13477dup;p.Gly136_Ser191dup *IKZF2* variant, we embarked on a
439 detailed immunological assessment of P1. detailed immunological assessment of P1.

440 Immunophenotyping of this patient with DN *IKZF2* deficiency revealed striking
441 differences from previous homozygous and heterozygous LOF patients and mice. For 441 differences from previous homozygous and heterozygous LOF patients and mice. For
442 example, P1 NK cells were phenotypically immature and likely hyperactive due to example, P1 NK cells were phenotypically immature and likely hyperactive due to elevated IFN-γ production and reduced intracellular perforin and granzyme B expression
444 **(Fiqure 3**). In contrast, other reported patients had NK cell lymphopenia^{8,9} or normal NK 444 (**Figure 3**). In contrast, other reported patients had NK cell lymphopenia^{8,9} or normal NK
445 development⁷. Furthermore, while IKZF2^{-/-} mice have normal NK cell frequencies²¹, NK 445 development⁷. Furthermore, while *IKZF2^{-/-}* mice have normal NK cell frequencies²¹, NK 446 cells from NKp46-mutant mice (Noé) show elevated Helios expression and effector
447 function, which modulates protective memory CD4⁺/CD8⁺ T cell development⁵². The 447 function, which modulates protective memory $CD4'/CD8$ ⁺ T cell development⁵². The 448 study of P1 has thus revealed a previously unappreciated role for Helios in human NK
449 cell development and function and calls for more in-depth studies in the future. cell development and function and calls for more in-depth studies in the future.

450 Helios has been extensively studied in mouse Tregs⁴², but its role in human Tregs has
451 remained relatively unclear. Previous CRISPR-mediated KO studies by our co-authors 451 remained relatively unclear. Previous CRISPR-mediated KO studies by our co-authors
452 found that Helios is dispensable for lineage stability and suppressive function in fully 452 found that Helios is dispensable for lineage stability and suppressive function in fully
453 differentiated Tregs²⁷, whereas germline homozygous or heterozygous LOF IKZF2 453 differentiated Tregs²⁷, whereas germline homozygous or heterozygous LOF *IKZF2*
454 variants caused a proinflammatory Treg phenotype associated with increased IL-2 and variants caused a proinflammatory Treg phenotype associated with increased IL-2 and 455 IFN-γ production, but intact suppressive function^{7,8}. Our functional studies with this DN
456 *IKZF2* variant confirm that it is not required for Treg development, but that it is essential 456 *IKZF2* variant confirm that it is not required for Treg development, but that it is essential
457 for inhibition of IL-2 expression and many other cytokines. Although functional 457 for inhibition of IL-2 expression and many other cytokines. Although functional 458 suppression of T cell proliferation appeared normal, aberrant production of many T_H 458 suppression of T cell proliferation appeared normal, aberrant production of many T_H
459 cytokines likely contributes to a functional defect in immune regulation *in vivo* (**Figure** 459 cytokines likely contributes to a functional defect in immune regulation *in vivo* (**Figure** 460 **6**), which is exacerbated by the greater propensity of P1 naïve CD4⁺ T cells to **6**), which is exacerbated by the greater propensity of P1 naïve CD4⁺ T cells to differentiate into effector CD4⁺ T cell subsets (T_H1, T_H2, T_H9, T_{FH}). differentiate into effector CD4⁺ T cell subsets (T_H1, T_H2, T_H9, T_{FH}).

462 Taken together, we have defined the immune phenotype of a novel form of Helios
463 deficiency caused by a DN variant, which leads to severe congenital AIHA and atopic 463 deficiency caused by a DN variant, which leads to severe congenital AIHA and atopic
464 dermatitis¹⁰. This study identifies new players in the pathogenesis of these immune-464 dermatitis¹⁰. This study identifies new players in the pathogenesis of these immune-
465 mediated disorders and has significantly expanded our understanding of human Helios. 465 mediated disorders and has significantly expanded our understanding of human Helios,
466 including its regulation of naïve CD4 T cell differentiation into memory/effector subsets including its regulation of naïve CD4 T cell differentiation into memory/effector subsets 467 and NK cell development and function.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

⁴⁶⁹**ACKNOWLEDGEMENTS**

470 This work was supported in part by grants from the Canadian Institutes of Health
471 Research (PJT 178054 to S.E.T.; FDN-154304 to M.K.L.), Genome British Columbia 471 Research (PJT 178054 to S.E.T.; FDN-154304 to M.K.L.), Genome British Columbia
472 (SIP007) (S.E.T.), and BC Children's Hospital Foundation. S.E.T. holds a Tier 1 Canada 472 (SIP007) (S.E.T.), and BC Children's Hospital Foundation. S.E.T. holds a Tier 1 Canada
473 Research Chair in Pediatric Precision Health and the Aubrey J. Tingle Professor of 473 Research Chair in Pediatric Precision Health and the Aubrey J. Tingle Professor of
474 Pediatric Immunology. M.K.L. receives a BCCHR salary award and holds a Tier 1 474 Pediatric Immunology. M.K.L. receives a BCCHR salary award and holds a Tier 1
475 Canada Research Chair in Engineered Immune Tolerance. H.Y.L. is supported by a 475 Canada Research Chair in Engineered Immune Tolerance. H.Y.L. is supported by a
476 CIHR Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral 476 CIHR Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral
477 Award (CGS-D), University of British Columbia Four Year Doctoral Fellowship (4YF), 477 Award (CGS-D), University of British Columbia Four Year Doctoral Fellowship (4YF),
478 Killam Doctoral Scholarship. Friedman Award for Scholars in Health. and a BC 478 Killam Doctoral Scholarship, Friedman Award for Scholars in Health, and a BC
479 Children's Hospital Research Institute Graduate Studentship. M.V.S. is supported by a 479 Children's Hospital Research Institute Graduate Studentship. M.V.S. is supported by a
480 Vanier Canada Graduate Scholarship and 4YF. A.J.L. is supported by a CGS-D and Vanier Canada Graduate Scholarship and 4YF. A.J.L. is supported by a CGS-D and 481 4YF. M.S. is supported by a CGS-D and 4YF. We would like to acknowledge the Flow
482 Cytometry and Imaging cores at BC Children's Hospital Research Institute for providing 482 Cytometry and Imaging cores at BC Children's Hospital Research Institute for providing
483 the equipment for microscopy, flow cytometry, and cell sorting, the Biomedical 483 the equipment for microscopy, flow cytometry, and cell sorting, the Biomedical
484 Research Centre Sequencing Core (BRC-Seq) for their assistance with single-cell RNA 484 Research Centre Sequencing Core (BRC-Seq) for their assistance with single-cell RNA
485 Sequencing and data processing, The Centre for Applied Genomics, The Hospital for 485 sequencing and data processing, The Centre for Applied Genomics, The Hospital for
486 Sick Children, Toronto, Canada for their assistance with whole genome sequencing, 486 Sick Children, Toronto, Canada for their assistance with whole genome sequencing,
487 and the BC Children's Hospital BioBank for providing access to age-matched and sex-487 and the BC Children's Hospital BioBank for providing access to age-matched and sex-
488 matched control peripheral blood mononuclear cells. matched control peripheral blood mononuclear cells.

⁴⁸⁹**AUTHORSHIP CONTRIBUTIONS**

490 H.Y.L, A.L., and S.E.T. were responsible for study conception and design. H.Y.L.,
491 M.V.S., A.J.L., M.S., J.G., G.X.Y., S.L. performed experiments. A.M., C.V., A.L., S.M. 491 M.V.S., A.J.L., M.S., J.G., G.X.Y., S.L. performed experiments. A.M., C.V., A.L., S.M.
492 conducted genetic screening and variant prioritization. H.Y.L., M.S., M.P.F., M.S.K., A.M conducted genetic screening and variant prioritization. H.Y.L., M.S., M.P.F., M.S.K., A.M
493 performed bioinformatics analyses or provided computational resources. H.Y.L., M.V.S., 493 performed bioinformatics analyses or provided computational resources. H.Y.L., M.V.S.,
494 A.S., R.R., L.A., J.H., C.L.Y., M.C., E.H., Au.S., F.K.K., K.J.H., C.M.B., C.V., A.L., 494 A.S., R.R., L.A., J.H., C.L.Y., M.C., E.H., Au.S., F.K.K., K.J.H., C.M.B., C.V., A.L., 495 S.E.T. collected and analyzed clinical data. H.Y.L., M.V.S., A.J.L., M.S., A.M., J.G., 495 S.E.T. collected and analyzed clinical data. H.Y.L., M.V.S., A.J.L., M.S., A.M., J.G., 496 G.X.Y., M.K.L., S.E.T. analyzed and interpreted data. H.Y.L. and S.E.T. wrote the 496 G.X.Y., M.K.L., S.E.T. analyzed and interpreted data. H.Y.L. and S.E.T. wrote the
497 manuscript with input from all authors. All authors read and approved the final version of manuscript with input from all authors. All authors read and approved the final version of 498 the manuscript.

medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295301;](https://doi.org/10.1101/2023.09.09.23295301) this version posted September 11, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

499 **DISCLOSURE OF CONFLICTS OF INTEREST**
500 The authors declare no competing financial inter

The authors declare no competing financial interests.

501
502

 $\frac{1}{2}$

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

⁵⁰³**REFERENCES**

505 505 1. Chan AY, Torgerson TR. Primary immune regulatory disorders: a growing
506 universe of immune dysregulation. Curr Opin Allergy Clin Immunol. 2020;20(6):582-590. 506 universe of immune dysregulation. *Curr Opin Allergy Clin Immunol*. 2020;20(6):582-590.
507 2. Flinn AM. Gennery AR. Primary immune regulatory disorders: Undiagnosed 507 2. Flinn AM, Gennery AR. Primary immune regulatory disorders: Undiagnosed 508 needles in the haystack? Orphanet J Rare Dis. 2022;17(1):99.

508 needles in the haystack? *Orphanet J Rare Dis*. 2022;17(1):99.
509 3. Seidel MG. Autoimmune and other cytopenias in prin 509 3. Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies:
510 pathomechanisms, novel differential diagnoses, and treatment. *Blood*. 510 pathomechanisms, novel differential diagnoses, and treatment. *Blood.*
511 2014·124/15)·2337-2344 ⁵¹¹2014;124(15):2337-2344.

- 512 4. Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E,
513 Nowakowska E, Gil L. Autoimmune hemolytic anemia: current knowledge and 513 Nowakowska E, Gil L. Autoimmune hemolytic anemia: current knowledge and 514 perspectives. *Immun Ageing.* 2020;17(1):38. 514 perspectives. *Immun Ageing*. 2020;17(1):38.
515 5. Zanella A, Barcellini W. Treatme
- 515 5. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias.
516 Haematologica 2014;99(10):1547-1554. ⁵¹⁶*Haematologica*. 2014;99(10):1547-1554.
- 517 6. Tranekaer S, Hansen DL, Frederiksen H. Epidemiology of Secondary Warm
518 Autoimmune Haemolytic Anaemia-A Systematic Review and Meta-Analysis. J Clin Med. 518 Autoimmune Haemolytic Anaemia-A Systematic Review and Meta-Analysis. *J Clin Med.*
519 2021;10(6). ⁵¹⁹2021;10(6).
- 520 7. Hetemaki I, Kaustio M, Kinnunen M, et al. Loss-of-function mutation in IKZF2
521 leads to immunodeficiency with dysregulated germinal center reactions and reduction of 521 leads to immunodeficiency with dysregulated germinal center reactions and reduction of 522 MAIT cells. Sci *Immunol*. 2021;6(65):eabe3454.
- ⁵²²MAIT cells. *Sci Immunol*. 2021;6(65):eabe3454. 523 8. Shahin T, Kuehn HS, Shoeb MR, et al. Germline biallelic mutation affecting the
524 transcription factor Helios causes pleiotropic defects of immunity. Sci Immunol. 524 transcription factor Helios causes pleiotropic defects of immunity. *Sci Immunol.*
525 2021;6(65):eabe3981.
- ⁵²⁵2021;6(65):eabe3981. 526 9. Shahin T, Mayr D, Shoeb MR, et al. Identification of germline monoallelic
527 mutations in IKZF2 in patients with immune dysregulation. *Blood Adv*. 2022;6(7):2444-527 mutations in IKZF2 in patients with immune dysregulation. *Blood Adv.* 2022;6(7):2444-
528 2451.
- 528 **2451.**
529 **10.** ⁵²⁹10. Mohajeri A, Vaseghi-Shanjani M, Rosenfeld JA, et al. Dominant negative variants 530 in IKZF2 cause ICHAD syndrome, a new disorder characterised by
531 immunodysregulation craniofacial anomalies hearing impairment athelia and 531 immunodysregulation, craniofacial anomalies, hearing impairment, athelia and
532 developmental.delay *UMed*.Genet.2023 532 developmental delay. *J Med Genet*. 2023.
533 11. Kelley CM, Ikeda T, Koipally J, e
- 533 11. Kelley CM, Ikeda T, Koipally J, et al. Helios, a novel dimerization partner of 534 Ikaros expressed in the earliest hematopoietic progenitors. Curr Biol. 1998;8(9):508-534 Ikaros expressed in the earliest hematopoietic progenitors. *Curr Biol*. 1998;8(9):508-
535 515. 535 515.
536 12.
- 536 12. Hahm K, Cobb BS, McCarty AS, et al. Helios, a T cell-restricted Ikaros family
537 member that quantitatively associates with Ikaros at centromeric heterochromatin. 537 member that quantitatively associates with Ikaros at centromeric heterochromatin.
538 Genes Dev. 1998:12(6):782-796. ⁵³⁸*Genes Dev*. 1998;12(6):782-796.
- 539 13. Getnet D, Grosso JF, Goldberg MV, et al. A role for the transcription factor Helios
540 in human CD4(+)CD25(+) requlatory T cells. *Mol Immunol*. 2010;47(7-8):1595-1600. 540 in human CD4(+)CD25(+) regulatory T cells. *Mol Immunol*. 2010;47(7-8):1595-1600.
541 14. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW. Helios expression
- 541 14. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW. Helios expression is a
542 marker of T cell activation and proliferation. *PLoS One*. 2011:6(8):e24226. 542 marker of T cell activation and proliferation. *PLoS One*. 2011;6(8):e24226.
543 15. Serre K. Benezech C. Desanti G. et al. Helios is associated with
- 543 15. Serre K, Benezech C, Desanti G, et al. Helios is associated with CD4 T cells
544 differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 544 differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3
545 expression. PLoS One. 2011:6(6):e20731. 545 expression. *PLoS One*. 2011;6(6):e20731.
546 16. Leeansyah E. Svard J. Dias J. et al
- 546 16. Leeansyah E, Svard J, Dias J, et al. Arming of MAIT Cell Cytolytic Antimicrobial
547 Activity Is Induced by IL-7 and Defective in HIV-1 Infection. PLoS Pathog. 547 Activity Is Induced by IL-7 and Defective in HIV-1 Infection. *PLoS Pathog.*
548 2015;11(8):e1005072. ⁵⁴⁸2015;11(8):e1005072.

549 17. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros
550 transcription factor family member, differentiates thymic-derived from peripherally 550 transcription factor family member, differentiates thymic-derived from peripherally 551 induced Foxp3+ T requlatory cells. *J Immunol*. 2010;184(7):3433-3441. 551 induced Foxp3+ T regulatory cells. *J Immunol*. 2010;184(7):3433-3441.
552 18. Thornton AM, Lu J, Korty PE, et al. Helios(+) and Helios(-) Trec

552 18. Thornton AM, Lu J, Korty PE, et al. Helios(+) and Helios(-) Treg subpopulations
553 are phenotypically and functionally distinct and express dissimilar TCR repertoires. Eur 553 are phenotypically and functionally distinct and express dissimilar TCR repertoires. *Eur 554* J *Immunol.* 2019;49(3):398-412.

⁵⁵⁴*J Immunol*. 2019;49(3):398-412. 555 19. Kim HJ, Barnitz RA, Kreslavsky T, et al. Stable inhibitory activity of regulatory T
556 cells requires the transcription factor Helios. Science. 2015;350(6258):334-339. 556 cells requires the transcription factor Helios. *Science*. 2015;350(6258):334-339.
557 20. Sebastian M. Lopez-Ocasio M. Metidii A. Rieder SA. Shevach EM. Thorr

557 20. Sebastian M, Lopez-Ocasio M, Metidji A, Rieder SA, Shevach EM, Thornton AM.
558 Helios Controls a Limited Subset of Regulatory T Cell Functions. J Immunol. 558 Helios Controls a Limited Subset of Regulatory T Cell Functions. *J Immunol.*
559 2016;196(1):144-155.

⁵⁵⁹2016;196(1):144-155. 560 21. Cai Q, Dierich A, Oulad-Abdelghani M, Chan S, Kastner P. Helios deficiency has
561 minimal impact on T cell development and function. J Immunol. 2009:183(4):2303-2311.

561 minimal impact on T cell development and function. *J Immunol*. 2009;183(4):2303-2311.
562 22. Ross EM, Bourges D, Hogan TV, Gleeson PA, van Driel IR. Helios defines T 562 22. Ross EM, Bourges D, Hogan TV, Gleeson PA, van Driel IR. Helios defines T
563 cells being driven to tolerance in the periphery and thymus. *Eur J Immunol*. 563 cells being driven to tolerance in the periphery and thymus. *Eur J Immunol.*
564 2014;44(7):2048-2058.

⁵⁶⁴2014;44(7):2048-2058. 565 23. Skadow M, Penna VR, Galant-Swafford J, Shevach EM, Thornton AM. Helios
566 Deficiency Predisposes the Differentiation of CD4(+)Foxp3(-) T Cells into Peripherally 566 Deficiency Predisposes the Differentiation of CD4(+)Foxp3(-) T Cells into Peripherally
567 Derived Regulatory T Cells. J Immunol. 2019;203(2):370-378.

567 Derived Regulatory T Cells. *J Immunol*. 2019;203(2):370-378.
568 24. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, 568 24. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK. Helios+ and
569 Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J 569 Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. *J*
570 *Immunol*. 2013;190(5):2001-2008.

570 *Immunol*. 2013;190(5):2001-2008.
571 25. Gottschalk RA, Corse E, All 571 25. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced 572 Foxp3+ requlatory T cells. J Immunol. 2012;188(3):976-980. 572 Foxp3+ regulatory T cells. *J Immunol*. 2012;188(3):976-980.
573 26. Ng MSF, Roth TL, Mendoza VF, Marson A, Burt

573 26. Ng MSF, Roth TL, Mendoza VF, Marson A, Burt TD. Helios enhances the 574 preferential differentiation of human fetal CD4(+) naive T cells into regulatory T cells. Sci 574 preferential differentiation of human fetal CD4(+) naive T cells into regulatory T cells. *Sci Sci Immunol. 2019*;4(41). ⁵⁷⁵*Immunol*. 2019;4(41).

576 27. Lam AJ, Uday P, Gillies JK, Levings MK. Helios is a marker, not a driver, of 577 human Treg stability. Eur J Immunol. 2022;52(1):75-84. 577 human Treg stability. *Eur J Immunol*. 2022;52(1):75-84.
578 – 28. Nakagawa H, Sido JM, Reyes EE, Kiers V, C

578 28. Nakagawa H, Sido JM, Reyes EE, Kiers V, Cantor H, Kim HJ. Instability of 579 Helios-deficient Tregs is associated with conversion to a T-effector phenotype and 579 Helios-deficient Tregs is associated with conversion to a T-effector phenotype and 580 enhanced antitumor immunity. Proc Natl Acad Sci U S A. 2016;113(22):6248-6253.

580 enhanced antitumor immunity. *Proc Natl Acad Sci U S A*. 2016;113(22):6248-6253.
581 29. Lu HY, Sharma M, Sharma AA, et al. Mechanistic understanding of the comb 581 29. Lu HY, Sharma M, Sharma AA, et al. Mechanistic understanding of the combined 582 immunodeficiency in complete human CARD11 deficiency. J Allergy Clin Immunol. 582 immunodeficiency in complete human CARD11 deficiency. *J Allergy Clin Immunol.*
583 2021;148(6):1559-1574 e1513. 583 2021;148(6):1559-1574 e1513.
584 30. Sharma M, Fu MP, Lu ŀ

584 30. Sharma M, Fu MP, Lu HY, et al. Human complete NFAT1 deficiency causes a 585 triad of joint contractures, osteochondromas, and B cell malignancy. *Blood.* 2022. 585 triad of joint contractures, osteochondromas, and B cell malignancy. *Blood.* 2022.
586 31. Chessum L, Matern MS, Kelly MC, et al. Helios is a key transcriptional re

586 31. Chessum L, Matern MS, Kelly MC, et al. Helios is a key transcriptional regulator
587 of outer hair cell maturation. Nature. 2018;563(7733):696-700. 587 of outer hair cell maturation. *Nature*. 2018;563(7733):696-700.
588 32. Baine I, Basu S, Ames R, Sellers RS, Macian F. H

588 32. Baine I, Basu S, Ames R, Sellers RS, Macian F. Helios induces epigenetic
589 silencing of IL2 gene expression in regulatory T cells. J Immunol. 2013;190(3):1008-589 silencing of IL2 gene expression in regulatory T cells. *J Immunol*. 2013;190(3):1008-
590 1016. 590 1016.
591 33.

591 33. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development,
592 Maturation, and Clinical Utilization. *Front Immunol*. 2018:9:1869. 592 Maturation, and Clinical Utilization. *Front Immunol*. 2018;9:1869.
593 34. Burk CM, Coffey KE, Mace EM, et al. Immunodeficiency,

593 34. Burk CM, Coffey KE, Mace EM, et al. Immunodeficiency, centromeric instability,
594 and facial anomalies (ICF) syndrome with NK dysfunction and EBV-driven malignancy

and facial anomalies (ICF) syndrome with NK dysfunction and EBV-driven malignancy

595 treated with stem cell transplantation. *J Allergy Clin Immunol Pract*. 2020;8(3):1103-
596 1106 e1103. ⁵⁹⁶1106 e1103.

597 – 35. – Ruiz-Garcia R, Vargas-Hernandez A, Chinn IK, et al. Mutations in PI3K110delta
598 – cause impaired natural killer cell function partially rescued by rapamycin treatment. J 598 cause impaired natural killer cell function partially rescued by rapamycin treatment. *J*
599 Allergy Clin Immunol. 2018:142(2):605-617 e607. ⁵⁹⁹*Allergy Clin Immunol*. 2018;142(2):605-617 e607.

- 600 36. Petrelli A, Mijnheer G, Hoytema van Konijnenburg DP, et al. PD-1+CD8+ T cells
601 are clonally expanding effectors in human chronic inflammation. J Clin Invest. 601 are clonally expanding effectors in human chronic inflammation. *J Clin Invest.*
602 2018;128(10):4669-4681. ⁶⁰²2018;128(10):4669-4681.
- 603 37. Smirnova SJ, Sidorova JV, Tsvetaeva NV, et al. Expansion of CD8+ cells in 604 set anonytic anemia. Autoimmune hemolytic anemia. Autoimmune hemolytic anemia. Autoimmune hemolytic anemia. Autoimmune hemolytic anemia. 604 autoimmune hemolytic anemia. *Autoimmunity*. 2016;49(3):147-154.
605 38. Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The do
- 605 38. Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword:
606 Harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol. ⁶⁰⁶Harnessing PD-1 blockade in tumor and autoimmunity. *Sci Immunol*. ⁶⁰⁷2021;6(65):eabf4034.
- 608 39. Heizmann B, Kastner P, Chan S. The Ikaros family in lymphocyte development.
609 Curr Opin Immunol. 2018;51:14-23. ⁶⁰⁹*Curr Opin Immunol*. 2018;51:14-23.
- 610 40. Dovat S, Montecino-Rodriguez E, Schuman V, Teitell MA, Dorshkind K, Smale
611 ST. Transgenic expression of Helios in B lineage cells alters B cell properties and 611 ST. Transgenic expression of Helios in B lineage cells alters B cell properties and 612 promotes lymphomagenesis. J Immunol. 2005:175(6):3508-3515. 612 promotes lymphomagenesis. *J Immunol*. 2005;175(6):3508-3515.
613 41. Zhu X, Zhu J. CD4 T Helper Cell Subsets and Related I
- 613 41. Zhu X, Zhu J. CD4 T Helper Cell Subsets and Related Human Immunological Journal Disorders. *Int J Mol Sci.* 2020;21(21). 614 Disorders. *Int J Mol Sci*. 2020;21(21).
615 42. Thornton AM, Shevach EM.
- 615 42. Thornton AM, Shevach EM. Helios: still behind the clouds. *Immunology*.
616 2019;158(3):161-170. ⁶¹⁶2019;158(3):161-170.
- 617 43. Gakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory
618 T Cells and Human Disease. *Annu Rev Immunol*. 2020;38:541-566. ⁶¹⁸T Cells and Human Disease. *Annu Rev Immunol*. 2020;38:541-566.
- 619 44. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in 620 regulatory T cells. PLoS Biol. 2007;5(2):e38. 620 regulatory T cells. *PLoS Biol*. 2007;5(2):e38.
621 45. Polansky JK, Kretschmer K, Freyer
- 621 45. Polansky JK, Kretschmer K, Freyer J, et al. DNA methylation controls Foxp3
622 gene expression. *Eur J Immunol*. 2008:38(6):1654-1663. 622 gene expression. *Eur J Immunol*. 2008;38(6):1654-1663.
623 46. Wang ES, Verano AL, Nowak RP, et al. Acute p
- 623 46. Wang ES, Verano AL, Nowak RP, et al. Acute pharmacological degradation of 624 Helios destabilizes regulatory T cells. Nat Chem Biol. 2021;17(6):711-717. ⁶²⁴Helios destabilizes regulatory T cells. *Nat Chem Biol*. 2021;17(6):711-717.
- 625 47. Yates K, Bi K, Haining WN, Cantor H, Kim HJ. Comparative transcriptome
626 analysis reveals distinct genetic modules associated with Helios expression in 626 analysis reveals distinct genetic modules associated with Helios expression in
627 intratumoral requlatory T cells. Proc Natl Acad Sci U S A. 2018:115(9):2162-2167. 627 intratumoral regulatory T cells. *Proc Natl Acad Sci U S A*. 2018;115(9):2162-2167.
628 48. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximatior
- 628 48. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and 629 Projection for Dimension Reduction; 2018: arXiv: 1802.03426. 629 Projection for Dimension Reduction; 2018:arXiv:1802.03426.
630 49. Schmiedel BJ, Singh D, Madrigal A, et al. Impact of (
- 630 49. Schmiedel BJ, Singh D, Madrigal A, et al. Impact of Genetic Polymorphisms on 631 Human Immune Cell Gene Expression. Cell. 2018;175(6):1701-1715 e1716. ⁶³¹Human Immune Cell Gene Expression. *Cell*. 2018;175(6):1701-1715 e1716.
- 632 50. Dong S, Maiella S, Xhaard A, et al. Multiparameter single-cell profiling of human
633 CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-633 CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-
634 versus-host disease. *Blood*. 2013;122(10):1802-1812. 634 versus-host disease. *Blood*. 2013;122(10):1802-1812.
635 51. Rosenblum MD, Way SS, Abbas AK. Regu
- ⁶³⁵51. Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. *Nat Rev* ⁶³⁶*Immunol*. 2016;16(2):90-101.
- 637 52. Narni-Mancinelli E, Jaeger BN, Bernat C, et al. Tuning of natural killer cell
638 reactivity by NKp46 and Helios calibrates T cell responses. Science. 638 reactivity by NKp46 and Helios calibrates T cell
639 2012;335(6066):344-348. ⁶³⁹2012;335(6066):344-348.
- 640

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

⁶⁴²**TABLE LEGENDS**

⁶⁴³**Table 1. Summary of major hematological and immunological laboratory parameters.** Tabulation of patient hematological and immunological laboratory values 645 compared to age-specific reference ranges. $\frac{1}{2}$ value measured while patient was on 646 intravenous immunoglobulin replacement. TREC, T cell receptor excision circle; DAT, 647, direct antiqlobulin test: HGB. hemoglobin. direct antiglobulin test; HGB, hemoglobin.

⁶⁴⁸**FIGURE LEGENDS**

⁶⁴⁹**Figure 1. Clinical phenotype of the patient.** A) Family pedigree of the patient. Filled symbols indicate affected individuals. Arrow represents index patient. Known genotype 651 is marked. B-I) Hematological parameters measured in the patient over time. Shaded
652 regions=age-specific reference ranges. J) Sanger seguencing of DNA extracted from 652 regions=age-specific reference ranges. J) Sanger sequencing of DNA extracted from
653 whole blood of the patient. Primers were designed to flank the breakpoint. K) Schematic 653 whole blood of the patient. Primers were designed to flank the breakpoint. K) Schematic
654 representation of the impact of i) the c.406+540_574+13477dup IKZF2 variant on the 654 representation of the impact of i) the c.406+540_574+13477dup *IKZF2* variant on the 655 genomic level. Red inset=exon 5 duplication. Blue inset=Sanger sequencing primer genomic level. Red inset=exon 5 duplication. Blue inset=Sanger sequencing primer 656 location; and ii) the p.Gly136_Ser191dup Helios variant on the protein level. Red
657 inset=zinc finger 2 and 3 duplication. Var., variant: WT, wild-type: ZF, zinc finger: P1, 657 inset=zinc finger 2 and 3 duplication. Var., variant; WT, wild-type; ZF, zinc finger; P1, 658 patient 1. patient 1.

⁶⁵⁹**Figure 2. A novel** *IKZF2* **variant leads to reduced Helios protein expression and** ⁶⁶⁰**dominant interference of WT function.** A-B) HEK293 cells were transfected with 661 empty vector (EV), wild-type (WT) *IKZF2*, or p.Gly136_Ser191dup (variant) *IKZF2* alone
662 or in different combinations. Expression was determined by immunoblotting with both 662 or in different combinations. Expression was determined by immunoblotting with both
663 FLAG and Helios. n=5. C-E) Expression of Helios was detected in patient-derived and 663 FLAG and Helios. n=5. C-E) Expression of Helios was detected in patient-derived and
664 control lymphoblastoid cell lines (LCLs) and compared to negative (THP-1 monocytic 664 control lymphoblastoid cell lines (LCLs) and compared to negative (THP-1 monocytic
665 cells) and positive (Jurkat T leukemia cells) controls by C-D) immunoblot and E) flow 665 cells) and positive (Jurkat T leukemia cells) controls by C-D) immunoblot and E) flow
666 cvtometry. F) HEK293 cells were transfected with EV, WT, variant, or ratios of 666 cytometry. F) HEK293 cells were transfected with EV, WT, variant, or ratios of
667 WT:variant and subjected to immunofluorescence for detection of Helios (red, Alexa 667 WT:variant and subjected to immunofluorescence for detection of Helios (red, Alexa
668 Fluor 647), the nucleus (blue, DAPI), and F-actin (green, Phalloidin Alexa Fluor 488) 668 Fluor 647), the nucleus (blue, DAPI), and F-actin (green, Phalloidin Alexa Fluor 488)
669 busing a Leica SP5 Confocal and LAS X Software with a 100x objective lens. Scale using a Leica SP5 Confocal and LAS X Software with a 100x objective lens. Scale

It is made available under a CC-BY-NC-ND 4.0 International license.

670 bars=5μm. n=3. G-H) HEK293 cells were cotransfected with EV, *IKZF2* expression
671 plasmids at various ratios, pIL2-luc2, and Renilla luciferase. *IL2* promoter activity was 671 plasmids at various ratios, pIL2-luc2, and Renilla luciferase. *IL2* promoter activity was
672 defined as relative light units from different conditions normalized to EV. H) Pearson 672 defined as relative light units from different conditions normalized to EV. H) Pearson
673 correlation between *IL2* promoter activity and % variant/WT *IKZF2* plasmid transfected. ⁶⁷³correlation between *IL2* promoter activity and % variant/WT *IKZF2* plasmid transfected. 674 Shaded region=95% confidence interval. n=3. *p<0.05, **p<0.01, ***p<0.001, ⁶⁷⁵****p<0.0001. Ordinary one-way ANOVA with Šidák's multiple comparisons test.

⁶⁷⁶**Figure 3. P1 has impaired NK cell development and function.** A) Representative 677 flow cytometry dot plots showing CD3⁺CD56⁻ T cells, CD3⁻CD56⁺ NK cells, and 678 CD3⁺CD56⁺ NKT cells for P1 and a control. B-D) Frequency of B) T cells, C) NK cells, 679 D) NKT cells from A) in P1 and adult (HC^A) and pediatric (HC^P) controls. E) 680 Representative Helios histograms for T, NK, and NKT cells in P1 and controls
681 compared to a fluorescence minus one (FMO) control. Mean fluorescence intensities 681 compared to a fluorescence minus one (FMO) control. Mean fluorescence intensities
682 (MFI) are indicated. F-H) Quantification of Helios MFI in F) T cells, G) NK cells, H) NKT 682 (MFI) are indicated. F-H) Quantification of Helios MFI in F) T cells, G) NK cells, H) NKT
683 cells from P1 and controls. I-N) Frequency of I) CD56^{dim}, J) CD56^{bright} NK, K) CD16⁺, L) 683 cells from P1 and controls. I-N) Frequency of I) CD56^{dim}, J) CD56^{bright} NK, K) CD16⁺, L)
684 CD57⁺, M) CD27⁺, N) CD94⁺ NK cells in P1 compared to controls. O-P) Frequency of N) 684 CD57⁺, M) CD27⁺, N) CD94⁺ NK cells in P1 compared to controls. O-P) Frequency of N) 685 CD8⁺ and P) CD25⁺ NK cells in patient and controls before and after 4h PMA and 686 ionomycin (P/I) stimulation. Q-R) Frequency of Q) IFN- $\gamma^{\text{+}}$ and R) TNF- $\alpha^{\text{+}}$ NK cells in P1 687 and controls after P/I stimulation. S-T) MFI of S) granzyme B and T) perforin in
688 unstimulated P1 and control NK cells. U-V) Live NK cells from P1 or controls clustered unstimulated P1 and control NK cells. U-V) Live NK cells from P1 or controls clustered 689 on CD16, CD27, CD57, CD94, Helios, perforin, granzyme B, IFN-γ, and TNF-α. Number
690 of NK cells clustered for each group is indicated on the panels to the right. V) tSNE plots 690 of NK cells clustered for each group is indicated on the panels to the right. V) tSNE plots
691 from U) coloured based on CD16, CD27, CD56, CD57, or CD94 expression. A-N, Q-T) 691 from U) coloured based on CD16, CD27, CD56, CD57, or CD94 expression. A-N, Q-T)
692 P1 n=5, HC^A n=8, HC^P n=11. O-P) P1 n=3, HC n=8. *p<0.05, **p<0.01, ***p<0.001, 692 P1 n=5, HC^A n=8, HC^P n=11. O-P) P1 n=3, HC n=8. *p<0.05, **p<0.01, ***p<0.001, 693 ****p<0.0001. Ordinary one-way ANOVA with Šidák's multiple comparisons test.

**Figure 4. P1 CD8⁺ T cells are more differentiated and have enhanced cytokine
695 production.** A) Representative dot plots showing CD3⁺CD4⁻CD8⁺ and CD3⁺CD4⁺CD8⁻ 695 **production.** A) Representative dot plots showing CD3⁺CD4⁻CD8⁺ and CD3⁺CD4⁺CD8⁻ 696 T cells. B) Frequency of CD8⁺ T cells in P1 and adult (HC^A) or pediatric (HC^P) controls. 697 C) Representative contour plot of naïve (N), central memory (CM), effector memory 698 (EM), and TEMRA CD8⁺ T cells in the patient and a control. Quadrants corresponding
699 to each subset are shown to the right. D-G) Quantification of D) naive. E) CM, F) EM, G) to each subset are shown to the right. D-G) Quantification of D) naive, E) CM, F) EM, G)

It is made available under a CC-BY-NC-ND 4.0 International license.

700 TEMRA CD8⁺ T cells from C). H) Representative Helios histograms for CD8⁺ T cells 701 from P1 and three controls compared to a fluorescence minus one (FMO) control. Mean
702 fluorescence intensities (MFI) are indicated. I) Quantification of Helios MFI in different 702 fluorescence intensities (MFI) are indicated. I) Quantification of Helios MFI in different
703 CD8⁺ T cell subsets. J) Representative contour plots for PD-1⁺ CD8⁺ T cells in P1 and a 703 $CD8^+$ T cell subsets. J) Representative contour plots for PD-1⁺ CD8⁺ T cells in P1 and a 704 control. K) Quantification of J). L-Q) PBMCs stimulated 4h with PMA+ionomycin. L), O) 705 Representative contour plots for L) TNF- α^+ and O) IFN- γ^+ CD8⁺ T cells in P1 and a 706 control. M-N) Quantification of TNF- α^+ M) naïve and N) total memory CD8⁺ T cells. P-Q) 707 Cuantification of IFN-γ⁺ P) naïve and Q) total memory CD8⁺ T cells. A-Q) P1 n=5, HC^A 708 n=8, HC^P n=11. J-K) P1 n=3, HC^A n=8. *p<0.05, **p<0.01, ****p<0.001, ****p<0.0001. 709 Ordinary one-way ANOVA with Šidák's multiple comparisons test. R) Representative
710 histograms for dilution of Cell Proliferation Dye (CPD) eF450 in P1 or control CD8⁺ T 710 histograms for dilution of Cell Proliferation Dye (CPD) eF450 in P1 or control CD8⁺ T
711 cells after 4 days of stimulation with anti-CD3/CD28 beads at 1:32 bead to cell ratio. S) 711 cells after 4 days of stimulation with anti-CD3/CD28 beads at 1:32 bead to cell ratio. S)
712 Quantification of percent divided CD8⁺ T cells at 1:8, 1:16, 1:32 bead to cell ratios. The Quantification of percent divided CDB^+ T cells at 1:8, 1:16, 1:32 bead to cell ratios.
713 Shown are technical duplicates. Shown are technical duplicates.

**Figure 5. P1 CD4⁺ T cells are hyperactive and exhibit enhanced effector function.
715 A) Quantification of frequency of CD4⁺ T cells in P1 and adult (HC^A) or pediatric (HC^P)** 715 A) Quantification of frequency of CD4⁺ T cells in P1 and adult (HC^A) or pediatric (HC^P) 716 controls. B) Representative contour plot of naïve (N), central memory (CM), effector
717 memory (EM), and TEMRA CD4⁺ T cells in the patient and a control. Quadrants memory (EM), and TEMRA CD4⁺ T cells in the patient and a control. Quadrants
718 corresponding to each subset are shown to the right. C-F) Quantification of C) naïve, D) 718 corresponding to each subset are shown to the right. C-F) Quantification of C) naïve, D)
719 CM, E) EM, F) TEMRA CD4⁺ T cells from B). G) Representative Helios histograms for The CM, E) EM, F) TEMRA CD4⁺ T cells from B). G) Representative Helios histograms for
720 CD4⁺ T cells in P1 and three controls compared to a fluorescence minus one (FMO) 720 CD4⁺ T cells in P1 and three controls compared to a fluorescence minus one (FMO)
721 control. Mean fluorescence intensities (MFI) are indicated. H) Quantification of Helios 721 control. Mean fluorescence intensities (MFI) are indicated. H) Quantification of Helios
722 MFI in different CD4⁺ T cell subsets. I) Representative contour plots for PD-1⁺ CD4⁺ T 722 MFI in different CD4⁺ T cell subsets. I) Representative contour plots for PD-1⁺ CD4⁺ T 723 cells in P1 and a control. J) Quantification of I). K-V) PBMCs stimulated 4h with
724 PMA+ionomycin. K), M), O), Q), T) Representative contour plots for K) IL-2⁺ CD4⁺ M) 724 PMA+ionomycin. K), M), O), Q), T) Representative contour plots for K) IL-2⁺ CD4⁺ M) 725 IFN-γ' CD4', O) TNF-α' CD4', Q) IFN-γ'IL-4⁻ T_H1 and IFN-γIL-4' T_H2, T) IL-21'IL-9⁻ T_{FH} 726 and IL-21 IL-9⁺ T_H 9 cells in P1 and a control. Quadrant identities are shown on the 727 bottom right. Frequencies corresponding to each quadrant are included to the top right 728 of each panel. L), N), P), R-S), U-V) Quantification of L) IL-2⁺ CD4⁺, N) IFN- γ^+ CD4⁺, P) 729 TNF- α^+ CD4⁺, R) T_H1, S) T_H2), U) T_H9, V) T_{FH} cells. A-H), K-V) P1 n=5, HC^A n=8, HC^P

It is made available under a CC-BY-NC-ND 4.0 International license.

730 n=11. I-J) P1 n=3, HC^A n=8. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Ordinary one-
731 way ANOVA with Šidák's multiple comparisons test. W-Y) PBMCs stimulated with anti-731 way ANOVA with Šidák's multiple comparisons test. W-Y) PBMCs stimulated with anti-
732 CD3/CD28 beads at various bead to cell ratios for 4 days. W) T_H cytokines measured by 732 CD3/CD28 beads at various bead to cell ratios for 4 days. W) T_H cytokines measured by
733 LEGENDplex. X) Representative histograms for dilution of Cell Proliferation Dye (CPD) 733 LEGENDplex. X) Representative histograms for dilution of Cell Proliferation Dye (CPD)
734 eF450 in P1 or control CD4⁺ T cells stimulated at 1:32 bead to cell ratio. Y) 734 eF450 in P1 or control CD4⁺ T cells stimulated at 1:32 bead to cell ratio. Y)
735 Quantification of percent divided CD4⁺ T cells at 1:8, 1:16, 1:32 bead to cell ratios. 735 Quantification of percent divided CD4⁺ T cells at 1:8, 1:16, 1:32 bead to cell ratios.
736 Shown are technical duplicates. Shown are technical duplicates.

- 737 Figure 6. P1 Tregs have aberrant cytokine production and impaired suppressive
738 function. A) Quantification of frequency of CD3⁺CD4⁺CD8⁻CD25⁺CD127^{lo}FOXP3⁺
- 738 **function.** A) Quantification of frequency of CD3⁺CD4⁺CD8⁻CD25⁺CD127^{lo}FOXP3⁺ 739 Tregs in P1 and adult (HC^A) or pediatric (HC^P) controls. B) Representative Helios 740 histograms for Tregs in P1 and three controls compared to a fluorescence minus one
741 (FMO) control. Mean fluorescence intensities (MFI) are indicated. C) Quantification of 741 (FMO) control. Mean fluorescence intensities (MFI) are indicated. C) Quantification of
742 Helios MFI in Tregs. D) CpG methylation of the Treg-specific demethylated region 742 Helios MFI in Tregs. D) CpG methylation of the Treg-specific demethylated region
743 (TSDR) for P1 or control Tregs and Tconvs. Percent methylation at different TSDR CpG 743 (TSDR) for P1 or control Tregs and Tconvs. Percent methylation at different TSDR CpG
744 sites is indicated. Representative of n=2. E) Quantification of FOXP3 MFI in Tregs. F) 744 sites is indicated. Representative of n=2. E) Quantification of FOXP3 MFI in Tregs. F)
745 Quantification of PD-1⁺ Tregs. G-O) PBMCs stimulated 4h with PMA+ionomycin. G), I), Quantification of PD-1⁺ Tregs. G-O) PBMCs stimulated 4h with PMA+ionomycin. G), I), 746 N) Representative contour plots for G) IL-2⁺, I) IFN- γ^+ , IL-4⁺, and N) TNF- α^+ Tregs. H), 747 J-M), O) Quantification of H) IL-2⁺, J) IL-4⁺, K) IFN-γ⁺, L) IL-9⁺, M) IL-21⁺, O) TNF-α⁺ 748 Tregs. A-C), E), J-O) P1 n=5, HC^A n= 10, HC^P n=12. F-H) P1 n=3, HC^A n=8. *p<0.05, 749 **p<0.01, ***p<0.001, ****p<0.0001. Ordinary one-way ANOVA with Šidák's multiple
750 comparisons test. P) Isolated and expanded Tregs stimulated with anti-CD3/CD28 750 comparisons test. P) Isolated and expanded Tregs stimulated with anti-CD3/CD28
751 beads for 4 days. T_H cytokines measured by LEGENDplex. Shown are 3 technical 751 beads for 4 days. T_H cytokines measured by LEGENDplex. Shown are 3 technical 752 replicates. Q-R) Isolated and expanded Treas co-cultured at different ratios with control 752 replicates. Q-R) Isolated and expanded Tregs co-cultured at different ratios with control
753 CD3⁺ T responder (Tresp) cells. n=2. Q-R) Suppression of Q) CD4⁺ and R) CD8⁺ T cell 753 CD3⁺ T responder (Tresp) cells. n=2. Q-R) Suppression of Q) CD4⁺ and R) CD8⁺ T cell 754 proliferation. Significance determined by one-way ANOVA of areas under the curve. S)
755 T_H cytokines measured by LEGENDplex when co-culturing 1:16 bead:cell ratio 755 T_H cytokines measured by LEGENDplex when co-culturing 1:16 bead:cell ratio 756 stimulated P1 CD3⁺ Tresp with control Tregs. Shown are technical triplicates. stimulated P1 CD3⁺ Tresp with control Tregs. Shown are technical triplicates.

Figure 7. P1 naïve CD4⁺ T cells are more active and primed for effector function.
758 A-E) Single-cell RNA sequencing (scRNA-seq) of sorted CD3⁺CD4⁺CD25⁺CD127^{lo} 758 A-E) Single-cell RNA sequencing (scRNA-seq) of sorted CD3⁺CD4⁺CD25⁺CD127^{lo} 759 Tregs from P1 and 2 age-matched and sex-matched controls. A) Unstimulated Tregs

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

760 clustered and annotated using the DICE project and B) CD45RA/HLA-DR AbSeq
761 labelling. Panels represent the controls and P1 Tregs clustered together (overall) or 761 labelling. Panels represent the controls and P1 Tregs clustered together (overall) or
762 control or P1 Tregs alone. Included are legends with colours and numbers 762 control or P1 Tregs alone. Included are legends with colours and numbers
763 corresponding toleachicellitype-labelled. Doughnut-plots-are-included-below-each-panel 763 corresponding to each cell type labelled. Doughnut plots are included below each panel
764 to represent the frequency of each annotated cell type. C-E) Volcano plots comparing 764 to represent the frequency of each annotated cell type. C-E) Volcano plots comparing
765 stimulated patient and control C) CD45RA⁺HLA-DR⁻naïve. D) CD45RA⁻HLA-DR⁺ 765 stimulated patient and control C) CD45RA⁺HLA-DR⁻ naïve, D) CD45RA⁻HLA-DR⁺ activated, and E) CD45RA-766 activated, and E) CD45RA⁻HLA-DR⁻ Tregs. Red=significantly increased, 767 blue=significantly decreased, gray=non-significant. Vertical dashed line: fold
768 change=1.5, horizontal-dashed-line: FDR=0.05. Top 10-most-significant-genes-are 768 change=1.5, horizontal dashed line: FDR=0.05. Top 10 most significant genes are
769 labelled. F-H) scRNA-seg of sorted CD3⁺CD4⁺CD25⁻CD127^{hi} Tconv from P1 and 2 age-769 labelled. F-H) scRNA-seq of sorted CD3⁺CD4⁺CD25⁻CD127^{hi} Tconv from P1 and 2 age-770 matched and sex-matched controls. F-G) Unstimulated Tconv clustered and annotated
771 as in A-B). H-I) Volcano plots as in C-E) comparing stimulated patient and control H) 771 as in A-B). H-I) Volcano plots as in C-E) comparing stimulated patient and control H)
772 CD45RA⁺ naïve or I) CD45RA⁻ memory Tconvs. J) Gene set enrichment of differentially 772 CD45RA⁺ naïve or I) CD45RA⁻ memory Tconvs. J) Gene set enrichment of differentially 773 expressed genes between stimulated naïve patient and control Tconvs using EnrichR.
774 Shown are the combined scores and adjusted p-values. H=MSigDB Hallmark, 774 Shown are the combined scores and adjusted p-values. H=MSigDB Hallmark,
775 B=BioPlanet 2019, N=NCI Nature 2016, K=KEGG 2021 Human. K-P) PBMCs 775 B=BioPlanet 2019, N=NCI Nature 2016, K=KEGG 2021 Human. K-P) PBMCs
776 stimulated 4h with PMA+ionomycin. Quantification of stimulated K) IL-2⁺ naïve, L) IL-2⁺ 776 stimulated 4h with PMA+ionomycin. Quantification of stimulated K) IL-2⁺ naïve, L) IL-2⁺ 777 total memory, M) IFN- $\gamma^{\text{+}}$ naïve, N) IFN- $\gamma^{\text{+}}$ total memory, O) TNF- $\alpha^{\text{+}}$ naïve, and P) TNF- $\alpha^{\text{+}}$ 778 total memory CD4⁺ T cells. K-P) P1 n=5, HC^A n=8, HC^P n=11. ***p<0.001, ****p<0.0001. 779 Ordinary one-way ANOVA with Šidák's multiple comparisons test.

transfected

medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295301;](https://doi.org/10.1101/2023.09.09.23295301) this version posted September 11, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Table 1

